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Abstract  
 
Background: Of the 130 million babies born each year, 8 million die before their first birthday. A 
contributing factor in many of these deaths is poor pregnancy outcome as a result of complications 
of pregnancy. Preeclampsia (PE) and Gestational Diabetes Mellitus (GDM) are the common 
pregnancy complications that have no effective antenatal treatment other than steroid administration 
and timely delivery. Each occurs with an incidence of 5-10% and is responsible for the majority of 
obstetric and paediatric morbidity and mortality. These can permanently impact on lifelong health. 
Early detection of disease risk and onset is the first step in implementing efficacious treatment and 
improving patient outcome. In the context of antenatal screening, the objective is to identify 
biomarkers (e.g. proteins) that are informative of the risk of asymptomatic pregnant women 
subsequently developing complications of pregnancy.  Recent studies highlight the putative utility 
of tissue-specific nanovesicles (i.e. exosomes) in the diagnosis of disease onset and treatment 
monitoring. It was hypothesized that presymptomatic women who subsequently develop pregnancy 
complications display altered exosome profile (i.e. concentration and/or protein content) at first 
trimester of pregnancy (i.e. 6-12 weeks). The general aim of this thesis was to identify blood-borne 
biomarkers (i.e. exosomes) that may be used at the first antenatal visit to identify presymptomatic 
women who are at risk of developing complications of pregnancy. 
 
Methods: A time-series experimental design was used to establish pregnancy-associated changes in 
maternal plasma exosome concentrations during first trimester. Serial samples of plasma were 
collected from normal healthy pregnant women (n=10) at 6, 7, 8, 9, 10, 11 and 12 weeks of 
gestation. Plasma samples from pregnant women at 11-14 weeks of gestation who developed 
preeclampsia (n=15) and gestational diabetes mellitus (n=7) were also collected. Exosomes were 
isolated by differential and buoyant density centrifugation and characterised by size distribution and 
morphology using nanoparticles tracking analysis (NTA; NanoSight™) and transmission electron 
microscopy (TEM) respectively. The total number of exosome vesicles and placenta-derived 
exosome vesicles were determined by quantifying immunoreactive exosomal CD63 and a placenta-
specific marker (PLAP) by ELISA. Finally, the differentially expressed exosomal proteins and 
peptides were identified by Liquid Chromatography and Mass Spectrometry based approaches (LC-
MS/MS). Statistical analysis was performed using the Graph Pad Prism software. 
 
  
 
ii 
 
Results: EM and NTA identified the presence of 50 - 120 nm spherical vesicles in maternal plasma 
as early as 6 weeks of pregnancy. The number of exosomes in maternal circulation increased 
significantly (ANOVA, p=0.002) with the progression of pregnancy (from 6 to 12 weeks). The 
concentration of placenta-derived exosomes in maternal plasma (i.e. PLAP
+
) increased 
progressively with gestational age, from 6 weeks 70.6 ± 5.7 pg/ml to 12 weeks 117.5 ± 13.4 pg/ml. 
Regression analysis shows that week is a factor that explains >70% of the observed variation in 
plasma exosomal PLAP concentration, total exosome number only explains 20%.  
The total number of exosome was 1.31e
12 
± 1.60e
12
 (mean ± SD) during the first trimester in women 
who developed Gestational Diabetes Mellitus (GDM) in second trimester and 1.09e
11
 ± 3.17e
10
 in 
women who developed Preeclampsia (PE). The statistical analysis showed that the total number of 
released exosomes in the first trimester of pregnancy complicated with GDM was three- fold higher 
than normal pregnancy and the concentration of the exosomes released from the placental cells was 
twofold compared to PLAP concentration in normal pregnancy. In addition, a significant (p<0.001) 
increase in the cumulative number of exosomes was observed during the first trimester of 
preeclamptic condition when compared with the first trimester normal pregnancy condition. 
 
Conclusion: This study presents longitudinal data on placental-derived exosomes in the first 
trimester of pregnancy, starting from as early as 6 weeks. Early detection of women at risk of 
pregnancy complications would provide opportunity to evaluate appropriate intervention strategies 
to limit acute adverse sequelae. The rationale for developing early pregnancy screening tests is not 
only for the management of the contemporaneous pregnancy but also to optimise lifelong and 
intergenerational health. If this can be achieved, it will provide an opportunity for early assessment 
of risk and the implementation of an alternative clinical management strategy to improve outcome 
for both the mother and the baby. 
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CHAPTER I 
1. INTRODUCTION 
 
1.1    Key concepts and variables 
Pregnancy induces a number of alterations to maternal physiology for maintaining the correct 
course of pregnancy; however, when the maternal changes do not occur properly pathological 
complications appear such as gestational diabetes mellitus (GDM), preeclampsia (PE) and 
intrauterine growth restriction (IUGR) [1]. The in depth understanding of the aetiology of these 
complications is lacking that limits our ability to identify and implement efficacious management 
and intervention strategies to ameliorate adverse effects for both mother and baby arising from these 
complicated pregnancies [2]. The situation is further exacerbated by the lack of reliable screening 
test to identify presymptomatic women who are at risk of developing complications of pregnancy. 
Recent studies highlight the putative utility of tissue-specific nanovesicles (e.g. exosomes) in the 
diagnosis of disease onset and treatment monitoring [3-5]. To date, there is a paucity of data 
defining changes in the release, role and diagnostic utility of placenta-derived nanovesicles (e.g. 
exosomes) in pathological pregnancies. Exosomes are nanovesicles that are released from viable 
cells into the body fluids under certain pathological conditions [6]. Exosomes carry proteins, 
microRNA and bioactive lipids that are informative of disease risk [7].  Exosomes are expected to 
be released from different cells in particular from placental trophoblast cells carrying proteins 
(biomarkers) in abnormal concentration into the maternal circulation in pathological pregnancies [8, 
9].  
 
Keywords: pathological pregnancies, biomarker, exosome 
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1.2  Background and motivation to perform the study 
Pathological pregnancies i.e. preeclampsia and gestational diabetes mellitus occur at a rate of 5-
10% each in all pregnancies and the incidence of these events is increasing in Australia and other 
developed nations [2] . These common pregnancy pathologies are diagnosed at late second or third 
trimester when the underlying pathology is most likely established. The currently available 
management to combat these complications are not preventative. Once the condition is diagnosed, 
the management aims at limiting further maternal as well as perinatal complications to develop 
arising from these conditions. Pregnant women developing these complications remain 
asymptomatic in early gestational weeks (i.e. first trimester); however, when they develop 
symptoms generally in the late second or early third trimester, those conditions become clinically 
overt and is out of capability to reverse the conditions towards normal healthy pregnancy [2]. 
Therefore, developing an effective way to screen presymptomatic pregnant women in the first 
trimester to detect pathological pregnancies from early stage is a challenge and there are many 
opportunities and scopes to undertake research studies in this arena.  
 Literature Review  
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CHAPTER II 
2. LITERATURE REVIEW 
2.1 Human pregnancy 
Pregnancy represents a significant homeostatic challenge to all body systems [10]. The progressive 
physiological changes that occur during pregnancy are essential to support and protect the 
developing fetus and also to prepare the mother for parturition [10] . This usually causes no major 
problems for healthy women. In the presence of clinical or subclinical pathology, the normal 
physiological changes of pregnancy can place significant strain on already compromised systems, 
threatening the lives of both mother and fetus [10]. Pregnancy is a time of great maternal metabolic 
and physiological challenges in order to adapt the mother to the needs of the developing fetus [11]. 
In pregnancy, the placenta plays the pivotal role in bringing out maternal physiological changes and 
fetal development. The placenta is a multifunctional organ as well as a rich source of several 
pregnancy associated hormones that influences fetal, placental and maternal metabolism [12]. 
Therefore, normal uncomplicated healthy pregnancy essentially relies on healthy placental 
development. 
Successful pregnancy requires adequate implantation and invasion of the trophoblast [13, 14]. For 
the initial phase of trophoblast growth, the trophoblast must adopt an invasive phenotype and 
induce the formation of feto-maternal circulation via maternal vascular system remodelling [15]. 
This invasion process occurs during the early first trimester of pregnancy and does not go beyond 
the proximal third of the myometrium. This process is regulated by different soluble endocrine 
mediators i.e. autacoids secreted by the placental cells and is associated with an increased 
production of pro-inflammatory cytokines and chemokines [16]. Optimum and adequate 
proinflammatory, procoagulatory and immunosuppressive environment in the maternal circulatory 
system as well as vascular remodelling of the maternal uterine blood vessels to establish feto-
maternal circulation essentially determine the outcome of pregnancy as normal to continue up to 
term delivery.  
 
2.2 Aetiology of pregnancy pathologies  
There are various pathologies that may occur during pregnancy such as gestational diabetes 
mellitus, preeclampsia and intrauterine growth restriction. Though the exact aetiology of these 
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conditions is not fully understood but it is considered that the placenta plays a vital role in 
developing these pathologies [17]; however, disordered placentation in terms of vascular connection 
establishment is considered responsible for evolving the complications [18]. 
During normal healthy pregnancy, the extravillous trophoblast cells invade into the inner third of 
the myometrium and the spiral arteries lose their endothelium and most of their muscle fibres [19]. 
These structural modifications are associated with functional alterations, such that spiral arteries 
become low-resistance and high-capacitance vessels, and thus become less sensitive or even 
insensitive to vasoconstrictive substances [20]. Therefore, there is effective first trimester invasion 
of trophoblast cells into the maternal uterine spiral arterioles. However, in most of the pregnancy 
complications this invasion process is anomalous leaving these vessels sensitive to vasoconstriction 
leading to placental ischemia [21]. 
Healthy pregnancy is associated with a state of relative systemic inflammation [22]. Notably, all the 
inflammatory changes of normal pregnancy are exaggerated in hypertensive disorders of pregnancy 
which manifest endothelial dysfunction and a wider stress response, including the acute phase 
response and metabolic effects of dyslipidaemia and increased insulin resistance [23]. 
During pregnancy, the placenta releases cortisol hormone (glucocorticoid) in higher concentration 
[22] which makes the pregnancy state more vulnerable to develop pregnancy-associated diabetes 
mellitus. Furthermore, the advanced maternal age, positive family history for diabetes and previous 
history of diabetes mellitus favour the condition (increased insulin resistance) to develop [22]. 
Pregnancy is a state of oxidative and nitrative stress resulting from generation of reactive oxygen 
and nitrogen species and this reactive oxygen species influence placental development [23]. 
However, in gestational diabetes mellitus (GDM) high glucose concentration yields excessive 
reactive oxygen species, especially superoxide free radicles that attributes to abnormal placentation 
[23]. 
 
2.3 Preeclampsia 
Preeclampsia is a multisystem disorder of pregnancy which is life threatening to both mother and 
fetus. This maternal syndrome is characterised by new onset of hypertension and proteinuria in the 
second half of pregnancy. The criteria that define preeclampsia are: onset at >20 weeks’ gestational 
age of 24-hour proteinuria ≥30 mg/day or, if not available, a protein concentration ≥30 mg (≥1+ on 
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dipstick) in a minimum of two random urine samples collected at least 4–6 hours but no more than 
7 days apart, a systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg as 
measured twice, using an appropriate cuff, 4–6 hours and less than 7 days apart, and disappearance 
of all these abnormalities before the end of the 6
th
 week postpartum in both early and late onset 
preeclampsia [24]. Nonetheless, some presentations of pregnancy-related hypertension combined 
with clinical or biochemical abnormalities or intrauterine growth restriction should also be 
considered as potential preeclampsia [19]. 
2.3.1 Brief description of preeclampsia 
Preeclampsia is a multisystem disorder that complicates 3%–8% of pregnancies in Western 
countries and constitutes a major source of morbidity and mortality worldwide [25]. The risk of pre-
eclampsia is 2-fold to 5-fold higher in pregnant women with a maternal history of this disorder. 
Risk factors have been identified, including a medical history of chronic hypertension, kidney 
disease, diabetes, obesity, age ≥35 years, and some pregnancy characteristics, such as twin or molar 
pregnancy, previous preeclampsia, or fetal congenital abnormality [18]. Preeclampsia may be life 
threatening for both mother and child, increasing both fetal and maternal morbidity and mortality. 
In mother, preeclampsia may cause premature cardiovascular disease, such as chronic hypertension, 
ischemic heart disease and stroke. Later in life, while children born after preeclamptic pregnancies 
and who are relatively small for gestational age at birth, have an increased risk of stroke, coronary 
heart disease, and metabolic syndrome in adult life [26]. The current sole curative treatment is 
delivery. Screening pregnant women at high risk and preventing recurrences are becoming key 
issues in the management of preeclampsia [19]. 
2.3.2  Pathophysiology and immunology of preeclampsia 
The placenta plays an important role in the pathophysiology of preeclampsia [27]. An inability to 
remodel maternal spiral arteries and subsequent suboptimal placental blood flow is one of the many 
underlying pathologies [27] (see figure 1). The placenta also produces factors that attribute to 
compromised blood flow and enhance placental damage [28]. 
The principal changes in the placenta with preeclampsia are decidual arteriolopathy, infarcts in the 
central area, abruption placentae and impaired growth and Tenney-Parker changes that refer to 
surface budding of the placental syncytium which is thought to be the adaptive changes to altered 
maternal blood flow [29]. There is also excessive systemic maternal inflammatory response in 
preeclampsia as placenta releases many cytokines and antiangiogenic factors when exposed to 
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preeclamptic environment [30]. These factors prevent proper placental development and 
establishment with uterine spiral arteries [29]. 
Preeclampsia manifests as a two stage disease. In first stage when the mother is asymptomatic, there 
is poor placentation due to inadequate uteroplacental circulation in hypoxic environment that leads 
to reperfusion injury, placental ischaemia and oxidative stress. This ischaemia leads to hypoxia that 
causes the release of proinflammatory, antiangiogenic and vasoconstrictive substances from the 
malfunctioning placenta that affect the maternal circulatory system and manifests as hypertension, 
proteinuria and glomerulopathies [31].  
The current understanding of pathophysiology of preeclampsia emphasises on a wide variety of 
target organ involvement during the process of this pregnancy vascular complication. In 
preeclampsia, the underlying pathogenesis involves defective deep placentation, oxidative and 
endoplasmic reticulum stress, autoantibodies to type-1 angiotensin II receptor, platelet and thrombin 
activation, intravascular inflammation, endothelial dysfunction and the presence of an 
antiangiogenic state [32].  
Furthermore, different immunological phenomena are implicated in preeclampsia pathogenesis, not 
merely defective placentation. In one study it was observed that during pregnancy natural killer 
cells and antigen presenting cells (including dendritic cells and macrophages) consisted a large 
proportion of the decidual leukocyte population, and were thought to modulate vascular 
remodelling and trophoblast invasion [33]. Additionally, T lymphocytes were involved in regulating 
maternal systemic immune tolerance that prevented the rejection of the fetal semiallograft and all 
these physiological processes attributed to normal healthy pregnancy [33].  
Recently several studies reported the association of differentially expressed maternal circulatory 
immunological molecules and development of preeclampsia. The gene for CD4+ CD25 (bright) 
regulatory T cells displayed significantly decreased expression in preeclamptic condition [34]. Also, 
the defective expression of T helper 17 cells in maternal peripheral blood circulation was found to 
be responsible for developing preeclampsia [35]. CD4 (+) and HLA-G (+) T cells were observed to 
be present in significantly higher concentration in peripheral blood of preeclamptic mothers [36]. 
Higher plasma levels of Hsp60, Hsp70 [37, 38] , and their specific antibodies, tumour necrosis 
factor-alpha (TNF-alpha) [39, 40], interleukin (IL)-1, IL-12, and soluble TNF-alpha-receptor I 
(sTNFRI) [37] and lower level of IL-10 [37, 40, 41] were determined in preeclampsia compared to 
healthy uncomplicated pregnancy. Other studies also found the role of complement activation and 
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regulation in preeclampsia. Maternal C4 deficiencies were most common in the preeclamptic 
placentae whereas more C1q was measured in the same tissue. Activated C4 and membrane-bound 
regulators CD55, CD46, and CD59 were observed abundantly in the syncytiotrophoblast, syncytial 
knots of preeclamptic placentae [42]. 
 
2.4 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is a syndrome characterised by “glucose intolerance with 
onset or first recognition during pregnancy” [43, 44]. 
2.4.1 Brief description of gestational diabetes mellitus 
GDM affects ~5% of all pregnancies and parallels the global increase in obesity and type 2 
diabetes.  In USA alone, GDM affects more than 135,000 pregnancies per year.  Lifestyle changes 
that impact adversely on caloric balance is thought to be a contributing factor in this emerging 
pandemic [45, 46]. The current ‘gold standard’ test for the diagnosis of GDM is the oral glucose 
tolerance test (OGTT) at 24–28 weeks of gestation [47]. Pathology is probably already established 
and reversal of the potential adverse perinatal outcomes may be restricted. The lack of a reliable 
early test for GDM has hampered the development of useful intervention therapies that may impact 
not only on the acute but also the long-term health outcomes. Thus, it is important to diagnose and 
predict GDM earlier so that appropriate management can be initiated and tailored to the needs of the 
patient in order to minimise perinatal complications and their sequelae. 
According to HAPO study in 2008 [48], there is a strong correlation between maternal glucose 
levels below those diagnostic of diabetes in early pregnancy and adverse pregnancy outcomes (i.e. 
increased birth weight of babies) that similarly occurs in GDM. 
2.4.2  Pathophysiology of GDM  
During pregnancy, maternal metabolic status gets altered with changes in hormones, growth factors 
and nutrients [49]. Most of the pregnancy hormones i.e. Human Chorionic Gonadotropin (HCG), 
Human Placental Lactogen (HPL), placental glucocorticoids are gluconeogenic which leads to 
excess glucose production in the maternal circulation [48]. This hyperglycaemia affects and alters 
the level of insulin, insulin like growth factors 1 and 2 (IGF1 and 2), Fibroblast Growth Factor 
(FGF-2), Vascular Endothelial Growth Factor (VEGF), Tumour Necrosis Factor (TNF-α) and leptin 
which ultimately play role in abnormal placentation through inhibition of trophoblast invasion, 
 Literature Review  
 
 
 
- 8 - 
 
placental angiogenesis and placental vascularisation [23]. This change becomes evident in early 
pregnancy (at the end of first trimester) [23]. 
On the other hand, there is imbalance between ROS formation and the antioxidant defense 
mechanisms of a cell or tissue which may lead to damage to the placenta [23]. Other than abnormal 
placentation the changes in substrates, growth factors and hormones are expected to be observed in 
the maternal circulation in GDM during early pregnancy which may enhance exosome release from 
different tissues and those exosomal biomarkers can be identified. 
 
2.5 Intrauterine growth restriction (IUGR) 
IUGR is usually defined as fetal weight below the 10
th
 percentile for gestational age as determined 
by antenatal ultrasound [50]. Fetal growth restriction is the failure of the fetus to reach its 
genetically predetermined growth potential due to adverse genetic or environmental factors [51]. 
2.5.1 Brief description of IUGR 
IUGR babies exhibit aberrant development and require higher neonatal intensive care [52]. In 
addition to the short-term risks, the long-term risk of developmental programming includes 
metabolic disorders later in life. Up to 63% of adult diabetes, hypertension and heart disease may be 
attributed to low-birth-weight conditions in conjunction with an accelerated newborn to adolescent 
weight gain and obesity [51]. 
2.5.2 Pathophysiology of IUGR and relationship with preeclampsia severity 
A key aspect of successful placentation is the invasion of extravillous trophoblasts and 
transformation of the decidual and intramyometrial portions of uterine spiral arteries [53].  
However, in IUGR, there are reductions in utero-placental blood flow as well as intervillous 
haemodynamic alterations resulting from retained spiral artery contractility as a result of inadequate 
remodelling by trophoblast cells [51]. The absence of optimal utero-placental blood flow through 
these unmodified vessels suggest that hypoxia, re-oxygenation, oxidative stress, or a combination of 
these, are the potential aetiologies for IUGR [51]. In fact, some genetic abnormalities and 
environmental cues like maternal under-nutrition during early pregnancy period are responsible for 
all these changes [51].  
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IUGR and preeclampsia display a common placental pathology, i.e. placental insufficiency [54] 
although some studies highlighted the separate entity of these two pregnancy complications. It was 
documented that IUGR can develop without the manifestation of preeclampsia [55]. The uterine 
artery pulsatility index shows a gradual increase with the gestational age in confirmed cases of 
IUGR without preeclampsia [56]. Also, different placental histopathological changes were observed 
in IUGR with preeclampsia and without preeclampsia [57]. Other studies found that IUGR was 
inconsistently related with preeclampsia and mostly as a result of severe preeclampsia [58, 59]. 
  
 Literature Review  
 
 
 
- 10 - 
 
 
 
 
Figure 1. Placentation in normal healthy pregnancy and pregnancy complicated with 
preeclampsia. In normal placental development, invasive cytotrophoblasts of fetal origin invade 
the maternal spiral arteries, transforming them from small-calibre resistance vessels to high-calibre 
capacitance vessels capable of providing placental perfusion adequate to sustain the growing fetus 
(upper panel). In preeclampsia, cytotrophoblasts fail to adopt an invasive endothelial phenotype. 
Instead, invasion of the spiral arteries is shallow and they remain small calibre, resistance vessels 
(lower panel) which may result in placental ischemia. (Ref: Karumanchi S. A. et al. 2005) 
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2.6 Biomarkers  
Biomarker is regarded as physiological or pathophysiologic biochemical or biomolecular alteration 
at the organ, tissue and cell or subcellular level in response to an exposure that is measureable in 
biological samples and became the signature of onset of disease, underlying disease process or 
phenotypic outcome [60]. Biomarkers are dynamic markers and their concentration can be 
influenced by a variety of confounders during pregnancy which include genetic, epigenetic, 
nutritional, behavioural, racial/ ethnic and many others [60]. 
 
2.7 Exosomes: tissue-specific nanovesicles in the diagnosis of disease onset and treatment 
monitoring 
Exosomes are bioactive nanovesicles released from all types of viable cells into almost all 
biological fluids, including urine, blood, ascitic fluid, cerebrospinal fluid and even fractions of body 
fluids such as serum, plasma and cell conditioned media. Exosomes are synthesized by inward 
blebbing of the plasma membrane and are secreted by exocytosis process into the extracellular 
milieu [61-63]. Transmission Electron Microscopy (TEM) has described the morphology of 
exosomes as cup-shaped after fixation, adhesion, negative staining and visualization. Exosomes 
float on sucrose gradients and their buoyant density ranges from 1.13-1.19 g/ml [4]. Biochemically, 
the membrane of these vesicles is a lipid bilayer containing cholesterol, sphingomyelin, ceramide 
and detergent resistant membrane domains (lipid rafts) in very high concentrations that contribute to 
the stability of the exosomes in different types of environment [64]. These vesicles predominantly 
play role in intercellular signalling via sequestration of signalling molecules i.e. cytosolic proteins 
or proteins from the endocytic compartment or plasma membrane as well as mRNA and miRNA 
that act upon other distal target cells to modify their activity [65]. Exosomal proteins are from the 
protein families’ tetraspannins, heat shock proteins and major histocompatibility complex (MHC) 
class I and II [66, 67]. 
Release of exosomes is dependent on the physiological state and the extracellular environment that 
also contribute to harbouring different proteins and mRNA content in exosomes [3]. The function of 
exosomes has been reviewed in several literatures. In particular, exosomes are capable of 
transferring the DNAs, microRNAs, non-coding RNAs and lipids with or without direct cell to cell 
contact and as such these nanosized vesicles display a key role as an intercellular messenger in cell-
to-cell communication [68]. The major role of exosomes is to carry the information by delivering 
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various effectors or signalling molecules between specific cells contributing in immune 
suppression, antigen presentation, inflammation, exchanging genetic information,  cell adhesion and 
waste management [68, 69]. This active interaction regulates various physiological and pathological 
conditions, including cancer, infectious diseases, and neurodegenerative disorders [70]. These 
varied functions enable exosomes to be utilised in different clinical implications to understand the 
physiology under normal condition and the pathophysiology of different disease conditions as well. 
2.7.1 Biogenesis of exosomes  
The suggested biogenesis of exosomes in Figure 2, separates them from all other extracellular 
vesicles (EVs) so far known [71]. They are formed in the late endosomal membrane compartment 
by inward budding of the limiting membrane of late multivesicular endosomes and multivesicular 
bodies (MVB) and contain cell surface–expressed proteins and cytosolic components [72]. They are 
actively secreted into the extracellular space by fusion of the MVB with the plasmatic membrane 
[72].  
2.7.2 Exosomal proteins 
While the composition of exosomes appears to be cell-specific, a subset of common proteins have 
been identified [72]. The lipid bilayer is composed of sphingomyelin [72]. Among the most 
commonly used markers for characterisation of exosomes are tetraspannin proteins, including: 
CD63, CD81; CD9; and CD82 [72].  Other families of common proteins in all exosomes include 
chaperone proteins such as: Hsc70 and Hsp90; cytoskeletal proteins including actin, tubulin and 
myosin; transport proteins; and annexins [72].  Exosomes derived from antigen-presenting cells 
(APC) express MHC-I and MHC-II on their surface [72]. 
2.7.3 Exosomes as biomarker 
Cell derived vesicles i.e. exosomes may behold the unique source of clinically relevant and many 
non-invasive biomarkers as they are believed to play in various pathological conditions. Cell-
lineage and state specific exosomes may harbour body fluid-based biomarkers of unparalleled 
accuracy [73]. Exosome specific membrane proteins provide markers enabling exosome identity 
and selection, while cell type and cell-condition specific protein, mRNA and miRNA provide a rich 
potential source of biomarkers [73]. Exosomes help the discovery of relatively less expressed 
biomarkers of different pathological conditions that normally remain undetected [73]. 
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Figure 2. Biogenesis of exosomes – schematic presentation of the endosomal pathway by which 
exosomes are generated and secreted. CG, Complex Golgi; RER, rough endoplasmic reticulum; 
MV, microvesicle; MVB, multivesicular body. (Ref: Salomon et al. 2013) 
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2.8 Placental exosomal biomolecules: role in placental and maternal physiology 
During pregnancy several kinds of microparticles including nanovesicles (i.e. exosomes) are 
secreted from the placenta into the maternal circulatory environment [74]. These vesicles containing 
various proteins, miRNA, mRNA and bioactive lipids play essential role in reproduction through 
adaptation of the maternal body system with the pregnancy related physiological changes [72]. 
Firstly, placental exosomes containing protein syncytin contributes to fusion of cytotrophoblast 
cells to form syncytiotrophoblast cells that are necessary for syncytiotrophoblast cells’ invasion into 
the maternal uterine spiral arterioles [75, 76]. Another study reported that exosomes secreted from 
the extravillous trophoblast cells promote vascular smooth muscle cell migration which is 
particularly helpful for maternal uterine spiral arterial remodelling and properly controlled 
placentation [77].  
Secondly, exosomes secreted from placenta consisting of specific proteins act upon target immune 
cells to provide immunosuppressive environment during pregnancy. Previously conducted several 
studies could isolate different proteins from trophoblast cells that exhibited their ability to suppress 
maternal immune system which is essential for fetal semiallograft survival. MHC class I chain 
related molecules [78], down regulated Natural Killer cell receptor (NKG2D) [78, 79], functional 
Fas ligand [80, 81] and TRAIL molecules [81], HLA-G and B7 family of immunomodulators [82] 
were isolated from first trimester placental tissues and these molecules suppressed T cell  signalling 
components [83, 84]. Lastly, placenta specific miRNA molecules were sorted in placental exosomes 
[85, 86] that showed the property of resistance against viral infection to protect the fetus during 
pregnancy [87-89]. 
Exosomes are a specific subtype of extracellular vesicles (EVs) of endocytic origin with the 
capacity to incorporate specific molecules such as proteins and miRNAs in response to changes in 
the microenvironment milieu (e.g. hypoxia). The human placenta constitutively produces and 
secretes EVs that enter into the maternal circulation and have a participation in the maternal 
adaption to pregnancy related physiological changes. In early pregnancy, the concentration of 
placenta derived exosomes in maternal blood increases dramatically. These exosomes are 
biologically active and exert various functions to maintain the pregnancy successfully. Placental 
exosomal concentration gradually increases throughout pregnancy and decline in late pregnancy 
[90].  
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2.9 Placenta-derived exosomes: a potential biomarker of pregnancy complications 
The human placenta is a fenestrated organ that produces and secretes exosomes which are released 
into the maternal peripheral blood circulation during pregnancy [1, 9, 91]. These exosomes are 
immunosuppressive as cause immunomodulatory decline in early pregnancy by suppressing the 
function of T cells and pluripotent carrying proteins, mRNA and miRNA which influence different 
biologic mechanisms throughout pregnancy [83]. There is evidence that exosomes are released in 
low concentration during normal pregnancy whereas this shedding from syncytiotrophoblast is 
enhanced in endothelial and immune-cell dysfunction which is associated with the placental 
pathophysiology in preeclampsia [91].  
Exosomes have been identified in plasma under both normal and pathological conditions.  There are 
a considerable number of proteins (biomarkers) commonly identified by proteomic analysis in 
plasma exosomes of pregnant women that are placenta-specific [92]. These placenta-specific 
exosome markers have been implicated to be involved in different pathological states of pregnancy. 
The concentration of exosomal proteins in plasma has been reported to be increased in association 
with disease severity and/or progression and in response to oxidative stress [5].  In preeclampsia, 
the impaired placental function with the placental apoptosis and necrosis causes increased release of 
microvesicles and nanovesicles (i.e. exosomes) [93, 94]. These exosomes contain different markers 
(proteins) that are actors or witnesses to the various stages of mechanisms of the disease [95]. In 
GDM pregnancies, oxidative stress and hyperglycaemia may be responsible for increasing the 
release of extracellular vesicles including exosomes into the maternal circulation that can be 
detected, characterised and may be of utility as early biomarkers of disease onset [71].  
 
2.10     Biomarkers for the prediction of preeclampsia with their performance and limitation 
Preeclampsia is a complex multisystem disorder of pregnancy that manifests in second trimester. 
The current preventive methods are based on obstetric history and clinical features which are not 
really helpful and the ultimate curative treatment is delivery which results in higher maternal as 
well as neonatal mortality and morbidity rate. Abnormal placentation with aberrant vasculogenesis 
is the basis of this pathology that begins in early first trimester [32]. All these findings necessitate 
the innovation of reliable non-invasive screening tests in first trimester that would allow for the 
early initiation of prophylactic therapies, institution of an appropriate model of care and recruitment 
of pregnant women at risk for interventions to ameliorate the condition.   
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Several research studies have been conducted to identify a set of parametres (i.e. biomarkers) in 
asymptomatic pregnant women’s blood in first trimester that can indicate abnormal placental 
function (see Table I). Commonly detected blood-borne biomarkers are- Pregnancy Associated 
Plasma Protein-A (PAPP-A), Placental Protein 13 (PP13), soluble Fms-like tyrosine kinase -1(sFlt-
1), pentraxin, inhibin-A, placental growth factor, vascular endothelial growth factor (VEGF) [96-
98]. Some miRNAs, lipids and enzymes have been found to be deregulated in preeclamptic 
condition, i.e. miR455- 3P and miR455- 5P [99], miR-1233 [100], Glycerophosphoserines-GP01, 
GP02, GP03 and Flavanoids-PK12 [101], matrix metalloproteinase-2 and 9 [102]. Several 
biomarkers were found to be upregulated and some were downregulated with the pathological 
changes. However, most of these biomarkers cannot be detected at significant level in early first 
trimester. The relationship of these biomarkers with preeclampsia needs to be verified by 
performing large scale study on different ethnic population. Additionally, it is important to discover 
a panel of biomarkers with greater predictive value which necessitates further research. Finally, the 
available proteomic approaches and methods to identify the biomarkers need to be robust as well as 
cost-effective to introduce in clinical setting.  
 
2.11 Final remarks 
According to the World Health Organization, over 346 million people worldwide, roughly the 
combined populations of the United States and Canada have pregnancy complications (e.g. pre-
eclampsia, GDM or IUGR) [100]. Therefore, it can be assumed that a large number (~15%) of the 
women who get pregnant will develop complications, which lead to maternal or fetal vital risk. 
Unfortunately, the incidence of disease alters physiological evolution of the fetal development as 
well as maternal health. In the context of antenatal screening, the objective of proteomic approaches 
is to identify proteins or peptides that are informative of the risk of pre-symptomatic early pregnant 
women who subsequently develop complications of pregnancy, meant a breakthrough for better 
management of the disease before symptoms begin. The exosomes research in human pregnancy is 
burgeoning and it is logical to expect that more exosomes-carrier molecules and mechanism of 
action will be revealed in the near future. 
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Table I. Commonly detected biomarkers in maternal blood to predict preeclampsia  
 
Serum level (↑/↓) Name of biomarkers 
Upregulated in preeclampsia Pregnancy associated plasma protein-A 
Placental protein-13/ Galectin family of proteins 
Inhibin-A 
P-selectin 
Pentraxin 3 
Fibronectin 
Heat-shock proteins (Hsp 70) 
Fms-like tyrosine kinase-1(SFlt1) 
Soluble Endoglin 
Cell free fetal DNA 
Adrenomedullin 
Calretinin 
Vimentin 
Downregulated in preeclampsia Annexin XI 
Placental growth factor (PlGF) 
Glypican 3 
insulin-like growth factor-2 mRNA-binding 
protein 3 (IGF2BP3) 
ICAM-1 
p-MAPK 
Bcl- 6 
 
(Ref: Muller-Deile et al. 2014, Shu C et al. 2014) 
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CHAPTER III 
3. HYPOTHESIS DEVELOPMENT 
 
3.1. Rationale and research approach 
Of the 130 million babies born each year, 8 million die before their first birthday [2]. A contributing 
factor in many of these deaths is poor pregnancy outcome as a result of pregnancy complications.  
Preeclampsia, gestational diabetes mellitus are important complications of pregnancy that have no 
effective antenatal management other than steroid administration and timely delivery [2]. Each of 
these complications occurs in 5 to 10% of pregnancies and are responsible for the majority of 
obstetric and paediatric morbidity and mortality [2].  When these pregnancy complications are 
diagnosed in the late second or early third trimester of pregnancy the ‘pathology’ is most likely 
well-established and the possibility to reverse or limit potential adverse effect on perinatal outcomes 
may be limited [2]. Early detection of predisposition to and/or onset of PE and GDM thus, are the 
first step in developing, evaluating and implementing efficacious treatment. Over the past 5 years, 
the role of exosomes in inter-cellular communication under both physiological and 
pathophysiological conditions has been recognised [10, 11]. The role of exosomal signalling in 
normal and pathological pregnancies, however, is only the beginning to be elucidated. Based on the 
available data, it was proposed that placental-derived exosomes might play a significant role in 
onset and development of pathologies in pregnancy (Figure 3).   
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3.2       Hypothesis  
Presymptomatic women who subsequently develop pregnancy complications may display altered 
placental-derived exosome profile in the first trimester of pregnancy  
 
3.3 General aim 
The aim of this project is to identify blood-borne biomarkers (i.e. exosomes) that may be used at the 
first antenatal visit to identify presymptomatic women who are at risk of developing complications 
of pregnancy 
 
3.4 Specific aims 
1. To characterise gestational age related changes in the concentration of placenta-derived 
exosomes at first trimester of pregnancy (i.e. 6-12 weeks) in plasma from women with 
normal pregnancies. 
2. To establish the placenta-derived exosomes profile (number of exosome release and their 
protein content) in early stages of pregnancy (first trimester) in plasma from pregnant 
women who subsequently develop GDM or PE  
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Figure 3. Schematic presentation of association between literature review and hypothesis. The 
arrow represents the total course of pregnancy. During the third trimester the pregnancy 
complications are established and affect the pregnancy outcome. The pregnancy complications are 
diagnosed currently at the second trimester. The hypothesis would test the relationship between 
pregnancy pathologies and placental exosome release including their protein content in the maternal 
circulation in the first trimester asymptomatic pregnant women predisposed to develop the 
pathologies in the second trimester. 
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CHAPTER IV 
4. METHODOLOGY 
 
4.1 Experimental design 
1. Plasma sample collection (Figure 4) 
 From women with normal healthy uncomplicated pregnancy (n=10, plasma was collected 
from 10 patients at 6-12 gestational weeks; total sample size was 70). These patients did not 
develop any complication during gestation. 
 From women with preeclampsia (n=15, plasma was collected from 15 patients at 11-14 
weeks; total sample size was 15). These patients developed preeclampsia (PE) in the late 
second or early third trimester of pregnancy. 
 From women with gestational diabetes mellitus (n=7, plasma was collected from 7 patients 
at 11-14 weeks; total sample size was 7). These patients developed gestational diabetes 
mellitus (GDM) at 22-28 weeks of pregnancy. 
 From non-pregnant women as control (n=5) 
2. Extracellular vesicles including exosomes isolation from plasma (Figure 5) 
 Differential ultracentrifugation (UT) and ultrafiltration 
3. Exosome purification (Figure 6) 
 Sucrose continuous gradient (0.25 M-2.5 M sucrose) 
 Sucrose (30%) cushion 
 ExoQuick kit 
4. Characterization of exosomes 
 Protein concentration determination by Bradford assay 
 Size Distribution of exosomes using Nanoparticle Tracking Analysis (NTA) by NanoSight 
 Transmission Electron Microscopic (TEM) analysis 
 
5. Quantification of exosomes 
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 Quantification of number of exosome particle by ELISA for CD63 (specific exosomal 
endocytic marker) 
 Placenta specific marker on exosome (PLAP) concentration measurement by ELISA for 
PLAP 
 
6. Mass spectrometric protein (exosomal protein) analysis (Figure 7) 
 Protein retrieval by MascotTM database searching against human species 
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Ethical clearance to perform the study: 
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Figure 4. Plasma sample collection. Plasma was collected from healthy normal pregnant women 
at 6-12 gestational weeks and women with pregnancy complications i.e. preeclampsia and 
gestational diabetes mellitus in first trimester (11-14 weeks). 
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Figure 5. Steps of exosome isolation from plasma. Differential ultracentrifugation and 
ultrafiltration processes were involved to isolate exosome nanovesicles from plasma sample. n=10 
(sample size) for each gestational age. 
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Figure 6. Different methods of exosome purification. Sucrose continuous gradient (0.25 M- 2.5 
M), 30% sucrose cushion and ExoQuick kit were utilised to purify the isolated exosomes from 
plasma. Density of fractions was measured and compared with exosomal density. 
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Figure 7. Workflow of exosomal sample processing for mass spectrometric protein analysis. 8 
M urea was applied to exosome rich sample to breakdown the membrane of vesicles that releases 
the proteins (content of exosomes) in sample and afterwards reduction by using Dithiothreitol 
(DTT), alkylation by ammonium bicarbonate, digestion by trypsin enzyme and desalting to clean 
the peptides were performed. 
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4.2 Methods 
Patient selection: Patients were selected based on certain demographic and clinical characteristics 
and plasma samples were collected in first, second and third trimester. In this study, only the first 
trimester samples were included. Ten healthy normal pregnant women at their 6-12 weeks (n=10 in 
each gestational week; total sample size is 70), 15 pregnant women at 11-14 weeks who developed 
preeclampsia later in their gestation (n=15 in first trimester) and 7 women at 11-14 weeks (n=7 in 
first trimester) who developed gestational diabetes mellitus in late second trimester were recruited. 
In addition, 5 non-pregnant women as control were recruited in this study with matching their 
demographic and clinical characteristics. Pregnant women underwent routine obstetrical care at 
Clinica Davilla (Santiago, Chile). All patients signed informed consent including the use of clinical 
data for research purposes and the protocol was approved by the Institutional Review Board of the 
University of Andes (Santiago, Chile). Obstetrical history and physical findings were recorded 
regarding previous spontaneous abortions, the course of previous pregnancies, hypertension, 
gestational diabetes and preeclampsia and different clinical and demographic characteristics i.e. 
maternal age, height, BMI, systolic blood pressure, HbA1c, basal glycaemic level. These 
characteristics were matched for each sample. Doppler ultrasound investigations of the umbilical 
arteries were also performed throughout the pregnancy period in all patients. The blood samples of 
those women were chosen who had none of these abnormal symptoms. Afterwards, all sample 
donors went through normal delivery at term. 
 
Sample collection: Peripheral venous blood samples were collected from women with normal 
(n=10), preeclamptic (n=15) and gestational diabetic pregnancies (n=7; diagnosed in the second 
trimester between 22-28 gestational weeks) in EDTA treated tubes (BD Vacutainer® Plus plastic 
serum tube) from which plasma samples were separated by centrifugation at 4,200 x g at 4
o
C for 10 
minutes. The separated plasma samples were aliquot and stored at -80
o
C until analysed (not more 
than three months). Care was taken to avoid repeated thaw and freeze cycles of the samples.  
A time series experimental design was used to establish the variation in plasma exosome 
characteristics during normal pregnancy. All experimental procedures were conducted within an 
ISO17025 accredited (National Association of Testing Authorities, Australia) research facility. All 
data were recorded within a 21 CERF part 11 compliant electronic laboratory notebook (Iris note, 
Redwood city, CA, USA). 
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Isolation of extracellular vesicles (EVs): One (1) ml of plasma from each patient was utilized to 
isolate exosomes. The plasma was diluted with 1 ml of PBS (pH 7.4) and extracellular vesicles 
including exosomes were isolated through differential ultracentrifugation and ultrafiltration process 
(see Figure 8). Centrifugation was initially performed at 2,000 x g at 4
o
C for 30 minutes (Thermo 
Fisher Scientific Ins., Asheville, NC, USA, Sorvall®, high speed microcentrifuge, fixed rotor angle: 
90
o
) followed by 12,000 x g at 4
o
C for 45 minutes to eliminate cell debris from the supernatant fluid 
(~2 ml). Then the resultant supernatant fluid (~2 ml) was transferred to an ultracentrifuge tube 
(Sorvall
®
 ultracentrifuge tubes) and was spun at 110,000 x g at 4
o
C for 2 hours (Thermo Fisher 
Scientific Ins., Asheville, NC, USA, Sorvall
®
, T-8100, fixed angle ultracentrifuge rotor). The pellet 
was suspended in PBS and filtration was performed though 0.22 µm filter (Steritop
TM
, Millipore, 
Billerica, MA, USA). The filtered solution was centrifuged finally at 110,000 x g at 4
o
C for 70 
minutes. The pellet was resuspended in 50 µl of PBS. Proteins were measured by using the DC
TM
 
Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) in each sample. 
 
Purification of exosomes: EVs isolated from plasma were used to determine the more suitable 
method for purifying the exosome vesicles. The isolated exosomes were further enriched in samples 
through different purification procedures: (i) sucrose continuous gradient, (ii) 30% sucrose cushion 
and (iii) ExoQuick
TM
 (System Bioscience).  
(i) EVs were added on the top of the 0.25M-2.5M sucrose continuous gradient which was prepared 
through utilization of gradient maker (Hoefer SG30 gradient maker, GE Healthcare, NSW, 
Australia) and ultracentrifuged at 110,000 x g at 4
o
C for 20 hours (Thermo Fisher Scientific Ins., 
Asheville, NC, USA, Sorvall
®
, SureSpinTM 630/360, Swinging-Bucket ultracentrifuge rotor). Ten 
fractions containing 3ml each were collected from bottom to top using highly reproducible 
automated fraction collector machine and the refractive indices were detected in those layers using 
the OPTi digital refractometre (Bellingham+Stanley Inc., Lawrenceville, GA, USA). The density of 
individual fractions was determined from the refractive index. Fractions that revealed the similar 
density to exosomes (1.11-1.19 g/ml) were again ultracentrifuged at 110,000 x g at 4
o
C for 2 hours 
after adding PBS (60 ml). The pellet were dissolved in 50µl of PBS and preserved at -80
o
C which 
seem to contain ~99% pure exosomes.  
ii) In 30% sucrose cushion purification method, the EVs containing exosomes vesicles was added 
onto the top of 30% sucrose cushion and then ultracentrifuged at 110,000 x g at 4
o
C for 70 minutes. 
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The comparatively pure exosomal solution was collected from the interface of the sample and the 
cushion by using 18G needle. This collected solution was further ultracentrifuged at 110,000 x g at 
4
o
C for 70 minutes. The pellets were dissolved in 50µl of PBS.  
iii) EVs were diluted in 250 µl PBS and then 63 µl of ExoQuick solution was added. This solution 
was incubated for overnight. Sample was centrifuged at 1,500 x g for 30 minutes and the pellet was 
resuspended in 100 µl PBS.   
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Figure 8. Flow diagram for exosome isolation and purification procedure based on 
differential ultracentrifugation, ultrafiltration and sucrose density gradient 
centrifugation. Flow chart for exosome purification procedure based on differential 
ultracentrifugation to isolate extracellular vesicles removing contaminating cellular debris 
and dead cells. The flow chart for the exosome purification procedure based on sucrose 
continuous gradient centrifugation showing exosome enriched fractions in yellow 4-7. 
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Protein concentration determination: Total exosomal protein was estimated by utilizing the 
DC
TM
 Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Sample was diluted with RIPA 
buffer (1:5) and then sonicated (Elmasonic S15H, iLABEQUIPMENT, New Jersey, USA) 3 times 
for 5 minutes to break down the membrane of the nanovesicles and release the protein content into 
the solution. In order to build the calibration curve; 0, 100, 200, 400, 800, 1000, 1500 times diluted 
solution of Bovine Serum Albumin (BSA, SIGMA-ALDRICH Life Science, Australia) were 
applied in triplicate manner into a 96 standard well plate. The samples were applied in duplicate 
manner. Two colorimetric reagents (Reagent A 25µl & Reagent B 200 µl, Bio Rad DC
TM
 Protein 
Assay) were applied and the plate was covered with aluminium foil and then incubated for 15 
minutes in dark for colour change. The absorbance was read at 750 nm wavelengths in a 
spectrophotometric plate reader (SPECTROstarNano, BMG Labtech, Australia). The device detects 
the absorbance of the colours that are produced after chemical reaction. From the absorbance 
protein concentration was determined. The limit of detection of the protein in BioRad DC
TM
 protein 
assay is 0.1-2.0 mg/ml. 
 
Identification of nanoparticles by NanoSight: NTA (Nanoparticle Tracking Analysis) 
measurements were performed using a NanoSight NS500 instrument (NanoSight NTA 2.3 
Nanoparticle Tracking and Analysis Release Version Build 0033) following the manufacturer’s 
instructions. The NanoSight NS500 instrument measured the rate of Brownian motion of 
nanoparticles. It contains a light scattering system that provides a reproducible platform for specific 
and general nanoparticle characterisation ((NanoSight Ltd., Amesbury, United Kingdom). Samples 
were processed in duplicate manner and diluted with PBS at concentration to obtain between 10 and 
100 particles per image (optimal value is ~50 particles x image). The samples were mixed before 
introduction into the chamber (temperature: 25
o
C and viscosity: 0.89 cP). The camera level was set 
to obtain an image that has sufficient contrast to clearly identify particles while minimising 
background noise during recording video (camera level: 10 and capture duration: 60 s). After 
capturing videos (2 videos per sample) these were processed and analysed. A combination of high 
shutter speed (450) and gain (250) followed by manual focusing enables optimum visualisation of 
maximum number of vesicles. A minimum of 200 tracks were completed per video. NTA post 
acquisition settings were optimised and kept constant between samples (Frames Processed: 1496 of 
1496, Frames per Second: 30, camera shutter: 20ms; Calibration: 139 nm/pixel, Blur: 3x3; 
Detection Threshold: 10; Min Track Length: Auto; Min Expected Size: Auto). Each video was then 
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analysed to calculate the mean, mode, and median size of particles together with an estimate of the 
number of particles. An Excel spreadsheet (Microsoft Corp., Redmond, Washington) was also 
automatically generated, showing the concentration at each particle size. 
 
Transmission electron microscopy (TEM): Exosome rich sample (30 µg protein) was fixed with 
an equal volume of buffer 3% (w/v) glutaraldehyde (pH 7.4) which is suitable for TEM. Exosome 
depleted sample was also prepared by performing ultrasonication  (Elmasonic S15H 
iLABEQUIPMENT, New Jersey, USA) 3 times for 5 minutes and was fixed with glutaraldehyde 
(3% w/v). These two samples were then applied to a continuous carbon grid and negatively stained 
with uranyl acetate (2%). The samples were observed and examined in an FEI Tecnai 12 
transmission electron microscope (FEITM, Hillsboro, Oregon, USA). 
 
Quantification of placental-derived exosomes: (i) Total exosome vesicles: the exosome 
concentration in maternal circulation was determined using the total exosomal CD63 protein 
markers which was measured by ELISA (ExoELISA
TM
, System Biosciences, Mountain View, CA) 
according to the manufacturer’s instructions. The samples containing 10 µg of exosomal protein 
were bound and immobilised to a micro-titre ELISA plate wells using a binding buffer. The sample 
was then incubated by using monoclonal exosome specific primary antibody (Anti CD63) for an 
hour at room temperature with shaking. The plate was washed 3 times for 5 minutes with the wash 
buffer solution and then incubated with exosome validated secondary antibody (1:5000) for an hour 
at room temperature with shaking. Plate was washed again and incubated with super-sensitive TMB 
ELISA substrate at RT for 45 minutes with shaking in dark. Finally by using the stop buffer 
solution desired level of colour change was achieved by terminating the reaction. The number of 
exosome particles was determined in the samples from the absorbance identified at 450 nm 
spectrophotometric analysis and also by using an exosome protein standard curve calibrated by 
NanoSight instrument (provided by ExoELISA
TM
 kit). (ii) Placental-derived exosomes: PLAP 
(Placental Alkaline Phosphatase) is a specific protein marker of exosomes that is predominantly 
released from the placental trophoblast cells. To quantify the concentration of exosomal PLAP, a 
commercial ELISA kit (MBS701995, San Diego, CA, USA) was used and the protocol was 
followed according to the manufacturer’s instructions. The samples containing 10 µg of exosomal 
protein (purified using sucrose continuous gradient) were added to each well of a micro-titre plate 
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coated with anti-PLAP antibody and incubated at 37
o
C for 30 min, then was washed 3 times for 20 
sec. 50 µl of HRP-conjugate (50 µl secondary antibody) was added to each well and incubated at 
37
o
C for 20 min. The plate was washed and incubated with 50 µl of substrate A and 50 µl of 
substrate B at 37
o
C for 15 min. The incubation was terminated using 50 µl of stop solution at RT 
for 2 min with shaking. Absorbance was measured at 450 nm. The concentration of PLAP was 
determined from the absorbance.  
 
Mass spectrometry for peptide profiling: 15 µl volumes containing 25 µg of protein from the 
exosomal fractions obtained in each gestational week were used for the LC-MS/MS sample 
processing. Reduction, alkylation, digestion and desalting were performed to remove all the 
contaminants from the sample and also to split the proteins into simple peptide form. Isolated 
exosome preparation was adjusted to 8 M urea in 50 mM ammonium bicarbonate (pH 8.5) solution. 
Reduction was performed with 20 mM Dithiothreitol (DTT) in 100 mM NH4HCO3 solution and was 
heated up at 60
o
C for an hour. Alkylation was done with 100 mM Iodoacetamide (IAA) in 100 mM 
NH4HCO3 and was incubated at 37
o
C for an hour. Trypsin (Promega) enzyme was used to digest 
the sample for overnight at 37
o
C and salts were removed using stage micro column tips which were 
prepared in Eppendorf gel loader tips using the Empore C18 membrane. Digested peptides were 
further extracted with 60 µl 0.1% Formic acid in Acetonitrile (ACN) and 0.1% Trifluoroacetic acid 
(TFA). The sample was then dried by centrifugal evaporation and then redissolved in 50 µl of 1% 
Formic Acid (HCOOH). The sample was centrifuged at 15000 x g at RT for 2 min and 40 µl 
volumes from the top was transferred to the mass spectrometer glass tubes and analysed by LC-
MS/MS. 5600 Triple TOF mass spectrometry-based profiling approach was utilised to identify 
peptides- which is a cutting edge Liquid Chromatography (LC) and Mass Spectrometry (MS) 
LC/MS/MS instrumentation. 
 
Database searching and protein identification: Peak lists for each LC-MS/MS run were merged 
into a single MASCOT generic format file for MASCOT searches. LC-MS/MS spectra were 
searched against the human protein database using MASCOT search library. Peptide identifications 
were deemed significant if the ion score was greater than 30. The digested protein samples were 
analysed using a 5600 Triple TOF mass spectrometer (AB/Sciex) to obtain initial high mass 
accuracy survey MS/MS data to identify the peptides present in the samples. The in depth 
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proteomic analysis using Information Dependent Acquisition (IDA) experiments on the 5600 Triple 
TOF MS utilized an enhanced MS survey scan (m/z 350–1500) followed by 50 data-dependent 
product ion scans of the 50 most intense precursor ions.   
 
Statistical analysis: Data were presented as mean ± SEM, for n=10 different patients with normal 
pregnancy, n=15 patients with preeclampsia, n=7 patients with gestational diabetes mellitus and 
n=5 non-pregnant women. The effect of gestational age on plasma exosome number, exosomal 
protein and PLAP concentrations were assessed using ANOVA, with variance partitioned between 
gestational age and subject. Statistical difference between group means was assessed by Dunnett’s 
test to compare each treatment to the control group where the data distribution approximates 
normality and by Mann-Whitney U-test for distribution independent data analysis. Two group 
means were statistically assessed by Student’s t-test. Statistical significance was defined as at least 
p<0.05.
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CHAPTER V 
                                                        5. RESULTS 
 
5.1 Clinical data analysis 
 
A set of demographic and clinical characteristics of pregnant women in the first trimester of 
pregnancy have been analysed and compared in three different groups: healthy uncomplicated 
pregnancies (n=10) and pregnancies complicated with preeclampsia (n=15) and gestational diabetes 
mellitus (n=7) that were diagnosed in second or third trimester of pregnancy. Maternal age, body 
weight, height, BMI, arterial blood pressure, echocardiographic findings, left and right uterine 
artery pulsatility index  (diagnosed with transvaginal or transabdominal uterine artery doppler 
ultrasound) have been presented in Table II, III and IV. All pregnant women included in this study 
were normotensive (systolic / diastolic BP) (i.e. mean ± SD value for normal pregnancy 107.2 ± 
10.94/64.62 ± 8.77; with GDM 111.4 ± 8.99/67.71 ± 9.12 and with PE 118.8 ± 13.71/71.93 ± 15.43 
mmHg), had singleton pregnancy with no other medical or obstetrical complications. Mean 
maternal age with healthy pregnancy outcome was 24 ± 6.01 years; 29.14 ± 6.28 years with GDM 
and 29.93 ± 6.26 years with PE. Maternal body mass index (BMI) was calculated 25.91 ± 4.31 
kg/m
2
 in those women who had uncomplicated pregnancies. Fetal and placental weights were 
within normal range for both complicated (GDM) and uncomplicated pregnancies. The average 
values for right and left uterine artery pulsatility index were identified as within normal range 
according to gestational age for pregnancies complicated with preeclampsia and gestational diabetes 
mellitus. A comparative analysis of these characteristics in three different groups has been 
presented in Table V. 
 
5.2  Exosome isolation and purification from plasma  
 
Comparison of different methods of purification of exosomes  
The total exosomal protein concentration was measured using DC
TM
 Protein Assay in the initial 
plasma sample and in the samples following several steps of ultracentrifugation. There were 20- 
fold reductions in the amount of total proteins in the exosome enriched sample following 
differential ultracentrifugation compared to total protein concentration in plasma (Figure 9A). The 
Results  
 
 
 
- 37 - 
 
protein was also estimated and compared following ultracentrifugation and 3 different methods of 
exosome purification i.e. using 30% sucrose, sucrose continuous gradient and ExoQuick
TM
 kit. The 
total protein concentration reduced significantly (p<0.05) in the samples following these three 
purification steps compared to ultracentrifugation simply (Figure 9B). However, ExoQuick yielded 
more protein in the sample in comparison with 30% sucrose and sucrose gradient; though the 
difference in protein concentration was negligible using sucrose gradient and sucrose cushion (p-
value was 0.115). 
The microsomal (including exosomes) sample following purification steps was analysed by the 
NanoSight, which is a nanoparticle tracking device. The majority of the nanoparticles with size 
range of 30-150 nm were present in the sucrose purified samples. On the contrary, ExoQuick 
purified sample yielded less exosome like vesicles revealing size range 30-300 nm (Figure 10). It 
indicated that exosomal population was enriched in the sample after purification procedures. 
The purity of these isolated vesicles was determined based on electron microscopic analysis, 
estimation of protein concentration, quantification of nanoparticles using NanoSight
TM
 technology 
and quantification of number of exosome vesicles using ELISA for exosome specific marker CD63. 
The analysis on the characterisation revealed that sucrose density gradient centrifugation procedure 
yielded pure exosome vesicles compared to other two methods. Therefore, sucrose density gradient 
centrifugation method was considered the best method of exosome purification as this method can 
yield higher protein amount that mostly originate from exosome nanovesicles showing size range of 
30-150 nm which is similar to reported exosomal size range. The mean ± SD value of exosome size 
was 98 ± 39 nm after sucrose density gradient centrifugation purification procedure which was 
determined using NanoSight
TM
 device. 
 
Exosome characterization 
Maternal plasma exosomes isolated by differential and sucrose density gradient centrifugation were 
characterised by a buoyant density of 1.122 to 1.197 g/ml (fractions 4 to 7; see Figure 8). 
Nanoparticle tracking analysis showed a particle size distribution in 200,000 x g pellet (Figure 11A) 
ranging from 30 to 300 nm in diameter that corresponds to microsomal fraction (including 
exosomes particles) with an average size of 147 ± 71 nm (mean ± SD). After the sucrose continuous 
gradient centrifugation, the enriched exosomal fractions (1.122 to 1.197 g/ml) were mixed and a 
particle size distribution ranging from 50 to 140 nm in diameter, with an average of 98 ± 39 nm 
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(mean ± SD) (Figure 11B) was obtained. Electron microscopy revealed the presence of spherical 
vesicles, with a typical cup-shaped appearance and diameters ranging from 30 to 120 nm (Figure 
11B, insert and Figure 12).  
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Table II. Clinical characteristics of patients in first trimester (6-12 weeks) of healthy normal 
pregnancy  
 
Patient Maternal Data Fetal and Placental Data First Trimester 
ID Age Weigh
t (Kg) 
Height 
(metre) 
BMI 
(Kg/m
2
) 
Fetal 
Sex 
Placent
al 
weight 
(grams) 
Fetal 
Weight 
(grams)  
Left 
IP 
Right 
IP 
Blood 
Pressure 
(systolic/ 
diastolic)  
34 23 54.5 1.55 22.68 M 610 3365 2.51 2.43 90/60 
39 21 54 1.62 20.57 NO 
DAT
A 
NO 
DATA 
NO 
DATA 
1.8 1.77 100/60 
48 22 108 1.73 36.08 F 712 3020 1.17 1.63 120/80 
59 28 69 1.63 25.97 M NO 
DATA 
3975 1.13 1.5 100/60 
61 19 57 1.49 25.67 F 702 3550 1.81 1.37 90/50 
81 36 66 1.51 28.94 M 569 3005 2.76 2.79 120/80 
85 31 54 1.52 23.37 NO 
DAT
A 
NO 
DATA 
NO 
DATA 
0.94 0.71 110/60 
104 20 64 1.51 28.06 M 731 3520 1.54 0.92 100/70 
106 31 62 1.65 22.77 NO 
DAT
A 
607 3885 3.4 1.49 110/60 
108 22 57 1.51 24.99 F 543 4175 1.79 1.08 110/70 
109 16 59 1.63 22.20 F 696 3095 1.92 1.13  120/60 
113 17 57.5 1.55 23.93 M 501 2660 2.26 1.99 104/60 
115 26 86 1.65 31.58 M 625 3690 1.64 0.69 120/70 
Mean ± 
SD 
24 ± 
6.01 
65.23 
± 
15.52 
1.58 ± 
0.07 
25.91 ± 
4.31 
 629.6 ± 
78.42 
3449 ± 
469.4 
1.89 
± 
0.69 
1.5 ± 
0.63 
107.2 ± 
10.94/64.
62 ± 8.77 
 
Data were presented as mean ± SD (range). Fetal sex ‘F’ indicates female fetus and ‘M’ indicates 
male fetus. Left and right uterine arterial pressure was measured as pulsatility index (IP). 
  
Results  
 
 
 
- 40 - 
 
 
Table III. Clinical characteristics of patients in first trimester (11-14 weeks) diagnosed with 
gestational diabetes mellitus (GDM) 
 
Patient Maternal Data Fetal and Placental Data First Trimester 
ID Age  Weight 
(Kg) 
Height 
(metre) 
BMI 
(Kg/m
2
) 
Fetal 
Sex 
Placental 
weight 
(grams) 
Fetal 
Weig
ht 
(gra
ms) 
Left 
IP 
Righ
t IP 
Blood 
Pressure 
(systolic/ 
diastolic) 
56 25 69 1.62 26.29 F 697 3720 1.65 1.22 110/60 
58 34 63 1.55 26.22 F 535 2340 1.2 0.88 120/80 
143 32 75 1.65 27.54 F 590 3190 0.66 0.54 120/80 
175 24 84 1.61 32.40 M 652 3530 1.25 1.2 100/60 
183 24 73 1.54 30.78 M 730 3800 1.52 1.43 120/70 
207 40 62 1.51 27.19 M 700 3635 0.91 1.21 100/60 
353 
 
25 40 1.58 16.02 NO 
DAT
A 
NO 
DATA 
NO 
DAT
A 
1.87 1.77 110/64 
Mean ± 
SD 
29.1
4 ± 
6.28 
66.57 ± 
13.91 
1.58 ± 
0.04 
26.64 ± 
5.23 
 650.7 ± 
74.75 
3369 
± 
547.
1 
1.29 
± 
0.42 
1.17 
± 
0.39 
111.4 ± 
8.99/67.7
1 ± 9.12 
 
Data were presented as mean ± SD (range). Fetal sex ‘F’ indicates female fetus and ‘M’ indicates 
male fetus. Left and right uterine arterial pressure was measured as pulsatility index (IP). 
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Table IV. Clinical characteristics of patients in first trimester (11-14 weeks) diagnosed with 
preeclampsia (PE) 
 
Patient Maternal data First Trimester of Pregnancy 
ID Age Weight 
(kg) 
Height 
(cm) 
ECO  Art. 
Pressure 
L 
Doppler 
R 
Doppler 
Gest. 
Age 
(weeks) 
Gest. 
Age 
(days) 
7 25 80 154 29/04/2008  2.58 1.05 13 6 
31 31 74 162 15/07/2008 120/70 1.4 2.03 12 4 
40 32 65 153 24/07/2008 120/70 2.37 3.2 13 1 
57 34 59 161 19/08/2008 110/70 2.53 4.4 13 4 
104 20 64 151 30/10/2008 100/70 1.54 0.92 12 6 
125 36 78.5 159 11/12/2008 120/80 2.17 2.03 12 3 
137 33 84.9 149 20/01/2009 130/30 2.12 3.06 11  
156 36 69.5  10/03/2009 130/80 0.85 0.92 13 1 
190 40 80 162 19/05/2009 110/80 1.07 0.94 12 5 
192 18 65 160 26/05/2009 112/70 1.91 3.13 11 1 
196 23 53 149 2/06/2009 100/60 2.79 5.21 12  
216 26 98 168 9/07/2009 140/80 1.46 2.71 12 6 
319 30 86 151 21/01/2010 110/70 1.95 1.31 13 2 
385 32 124 159 20/07/2010 146/102 1.17 2.01 13  
469 33 59 163 9/11/2010 115/75 1.28 1.06 12 2 
Mean 
± SD 
29.93 
± 
6.26 
75.99 ± 
18.02 
157.2 
± 5.97 
 118.8 ± 
13.71/71.93 
± 15.43 
1.81 ± 
0.60 
2.26 ± 
1.33 
12.27 ± 
0.70 
3.41 ± 
2.02 
 
Data were presented as mean ± SD (range). Fetal sex ‘F’ indicates female fetus and ‘M’ indicates 
male fetus. Left and right uterine arterial pressure was mentioned as L and R Doppler. The date 
when echocardiography (ECO) was performed has been mentioned. 
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Table V. Comparative analysis of clinical characteristics of pregnant women in first trimester 
diagnosed with normal healthy pregnancy, gestational diabetes mellitus and preeclampsia 
 
Condition Maternal Data First Trimester of Pregnancy 
 Age 
(years) 
Weight 
(kg) 
Height 
(metres) 
BMI 
(kg/m
2
) 
Left IP Right IP Blood Pressure 
(systolic/diastolic) 
Normal 
healthy 
pregnancy 
24 ± 
6.01 
65.23 ± 
15.52 
1.58 ± 
0.07 
25.91 ± 
4.31 
1.89 ± 
0.69 
1.5 ± 
0.63 
107.2 ± 
10.94/64.62 ± 8.77 
Gestational 
diabetes 
mellitus 
29.14 ± 
6.28 
66.57 ± 
13.91 
1.58 ± 
0.04 
26.64 ± 
5.23 
1.29 ± 
0.42 
1.17 ± 
0.39 
111.4 ± 8.99/67.71 
± 9.12 
Preeclampsia 29.93 ± 
6.26 
75.99 ± 
18.02 
1.57 ± 
0.05 
NO 
DATA 
1.81 ± 
0.60 
2.26 ± 
1.33 
118.8 ± 
13.71/71.93 ± 
15.43 
 
Data were presented as mean ± SD (range). Left and right uterine arterial pressures were measured 
as pulsatility index (IP). 
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  A     B 
 
Figure 9. Comparison of different methods of purification of exosomes. The total protein 
concentration in plasma and following differential ultracentrifugation (A). Comparison in protein 
concentration following ultracentrifugation (UT) and purification of exosomes using 30% sucrose, 
sucrose continuous gradient and ExoQuick (B). **Significant (p<0.001) reduction in total protein 
concentration following purification. †Exoquick solution yielded significant (p<0.05) amount of 
total protein compared to 30% sucrose and sucrose continuous gradient centrifugation methods of 
exosome purification.  
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Figure 10. Size distribution of exosome vesicles using nanoparticle tracking analysis 
(NanoSight) following exosome purification by sucrose continuous gradient, 30% sucrose 
cushion and ExoQuick
TM
. The nanoparticles with size range of 30-150 nm were present in higher 
population in exosomal sample purified by 30% sucrose and sucrose continuous gradient and of 30-
300nm in ExoQuick purified sample. The mean ± SD value of the exosome size after sucrose 
gradient purification was 98 ± 39 nm and 147 ± 71 nm after purification using ExoQuick
TM
 kit.  
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A      B 
 
Figure 11. Characterisation of exosomes from maternal circulation. Exosomes were isolated 
from women with uncomplicated pregnancies during first trimester by differential and buoyant 
density centrifugation (see Methods). (A) Representative particles size distribution of microsomal 
fraction. Exosomes were purified based on sucrose continuous gradient centrifugation. (B) 
Representative particles size distribution of enriched exosomal fractions. Insert: Representative 
electron micrograph of pooled enriched exosome fractions, Scale bar 200 nm. 
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Figure 12. Transmission Electron Microscopic analysis of exosomes from plasma of normal 
healthy pregnant women following purification by sucrose continuous gradient. Numerous 
spherical cup shaped exosome like vesicles were present. The mean size of exosomes detected in 
the electron microscopic analysis was 34.16nm. The scale bar is 200 nm in the left two figures and 
100 nm in the right figure.  
  
Results  
 
 
 
- 47 - 
 
5.3       Exosomal stability in frozen stored plasma 
This study utilised exosomes from frozen stored (30 days) plasma sample; therefore, it was 
important to evaluate exosomes’ stability in frozen condition. The stability of exosomes after a 
freeze and thaw cycle was assessed using fresh and frozen plasma. No significant difference was 
observed using fresh or frozen plasma in exosome quantification, exosomal marker expression, 
exosomal microRNA expression and exosomal protein content (Figure 13A-D and Table IX in 
Appendix A). 
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Figure 13. Characteristics of exosomes isolated from plasma immediately after phlebotomy 
and after 30 days stored at -80
o
C. (A) Number of exosome particles.  (B) Exosomes 
characterization. b1: electron microscope (scale bar 100 nm) and b2: Western blot for CD63 
(exosomal marker); lane 1: Fresh and lane 2: stored. (C) Expression of miRNA RNU6B in 
exosomes. (D) The Venn diagram of total number of proteins identified in fresh and stored 
exosomes isolated from plasma in normal healthy pregnant women (n=10) during the first trimester 
(6-12 weeks) 
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5.4 Plasma exosomal protein characterization in first trimester of normal healthy pregnancy     
Difference of exosome release in pregnant and non-pregnant women 
Exosomes were isolated from plasma during the first trimester in women with normal pregnancy 
(n=10) outcome without any complications and from women who were not pregnant (n=5). The 
number of exosomes was quantified in exosome rich samples using ELISA for CD63 (specific 
exosomal endocytic marker) where the total number of exosome particles in non-pregnant women 
was 0.6e
11
 ± 0.2e
11
 (mean ± SD) and in pregnant women during first trimester was 1.33e
11 
± 1.27e
11 
(mean ± SD) and the statistical analysis (Student’s t- test) was performed to compare between the 
samples. The number of exosomes displayed more than two- fold (p<0.05) increase in pregnant 
women’s plasma exosomes compared to non-pregnant women’s plasma exosomes (Figure 14). 
Placenta-derived exosomes increased during first trimester of normal pregnancy 
Pooled exosome-containing fractions (i.e. fractions 4 to 7) were further characterised by 
determining the number of exosome particle (NEP) and exosomal PLAP concentration in serial 
samples of maternal plasma obtained during the first trimester of pregnancy (i.e. 6-12 weeks). 
The gestational age variation in plasma exosome number was analysed by two-way ANOVA with 
the variance partitioned between gestational age and subject. A significant effect of gestational age 
was identified (n=69, one missing value, p<0.005). A post-hoc multiple range test was used to 
identify statistically significant (p <0.05) differences between pairwise comparisons (Figure 15A). 
In addition, a significant effect of subject was identified (n=69, one missing value, p<0.05) (Figure 
15B). In addition, NEP and gestational age (i.e. 6-12 weeks) displayed a significant positive linear 
relationship (r
2
 = 0.202, p < 0.001, n=69, one missing value). 
To assess gestational age associated variation in placenta-derived exosomes, exosomal 
immunoreactive (IR) PLAP was quantified using a commercial ELISA kit (see Methods). IR 
exosomal PLAP concentrations were analysed by two-way ANOVA with the variance partitioned 
between gestational age and subject. A significant effect of gestational age was identified 
(p<0.0001, n=69, one missing value) (Figure 15C). A post-hoc multiple range test was used to 
identify statistically significant (p <0.05) differences between pairwise comparisons (Figure 15D). 
No significant effect of patient on IR exosomal PLAP concentration was identified (p=0.123). 
Immunoreactive exosomal PLAP concentration and gestational age displayed a significant positive 
linear relationship (r
2
 = 0.711, p < 0.001, n=69, one missing value). 
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Specific placental-derived exosomes 
Exosomal PLAP concentration and exosome number were subjected to correlation analysis. The 
fitted linear model was described by the following equation: plasma exosomal PLAP pg/ml = 85.6 
+ 5.47 x 10
-11
 x exosome number/ml (p < 0.05, n= 69, one missing pair). The coefficient of 
determination (r
2
) was 0.78 (Figure 16A) that indicated the simultaneous increase in the total 
exosome vesicles per ml of plasma and the concentration of placenta specific exosome marker 
(exosomal PLAP in pg/ml). However, no linear correlation was observed. 
To estimate changes in the relative contribution of placental exosomes to total exosomes present in 
maternal plasma and to identify gestational age-related changes, the apparent PLAP content per 10
9
 
exosome (PLAP ratio) was determined. Overall PLAP ratio averaged 2.01 ± 0.33. The effects of 
gestational age on PLAP ratio were assessed by Kruskal-Wallis one-way ANOVA. No significant 
effect of gestational age on PLAP ratio was identified (p = 0.06) (Figure 16B). 
The number of total exosome particle released into the peripheral circulation (CD63), amount of 
placenta specific exosomal marker (PLAP) and placental exosomal contribution to total exosomes 
in the circulation (PLAP/CD63) in each individual gestational week of mid-first trimester have been 
provided in Table VI.  
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Figure 14. Exosome release in pregnant and non-pregnant condition. Exosomes were isolated 
from plasma during first trimester in women with normal healthy pregnancy and from non-pregnant 
women (control). The number of exosomes were quantified in the conditions and compared. The 
total number of exosome particles in non-pregnant women was 0.6e
11
 ± 0.2e
11
 (mean ± SD) and in 
pregnant women during first trimester was 1.33e
11
±1.27e
11 
(mean ± SD). Exosome release increased 
by twofold (p<0.05) during first trimester of pregnancy than non-pregnancy condition. 
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Figure 15. Exosome profiling across first trimester pregnancy. Enriched exosomal 
population (i.e. number of exosome particles) and placenta-derived exosomes (i.e. exosomal 
PLAP) were quantified in peripheral plasma of women in the first trimester of pregnancy 
by ELISA. (A) exosomes as particles per ml plasma. (B) individual variation in exosome 
number for each week (C) exosomal PLAP during first trimester of pregnancy (i.e. 6-12 
weeks). (D) individual variation in exosomal PLAP for each week. Data are presented as 
aligned dot plot and values are mean ± SEM. In A, two-way ANOVA **p= 0.0048, Dunn’s 
post-hoc test analysis = *p < 0.05 6 vs. 7 weeks and †p<0.005: 6 vs. 12 weeks. In C, two-way 
ANOVA ***p<0.0001, Dunn’s post-hoc test analysis = *p < 0.05 6 vs. 9 and 10 weeks, 
†p<0.005: 6 vs. 11 and 12 weeks, and ‡p<0.005: 8 vs. 11 and 12 weeks. 
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Figure 16. Contribution of placental-derived exosomes into maternal circulation. (A) 
Relationship between exosomal PLAP and total exosomes (particles per ml plasma) across first 
trimester of pregnancy (i.e. 6-12 weeks represented by colours). Coefficient of determination (r
2
) 
was 0.78 and p<0.05. (B) Ratio of specific placental exosomes and total exosomes. In A, values 
were mean ± SEM, Linear correlation (-). In B, Data were presented as aligned dot plot and values 
were mean ± SEM, two-way ANOVA p>0.05. 
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Table VI. Number of Exosome Particle (CD63 and PLAP) in First Trimester of Pregnancy 
Gestational age 
(week) 
CD63 (NEP) PLAP (pg/ml) PLAP/CD63 
6 (n=10) 3.36e
10 
±
 
2.3e
10
 67.10 ± 6.16 3.12e
-9 
± 2.12e
-9
 
7 (n=10) 1.45e
11
± 4.66e
10
 67.98 ± 12.93 5.09e
-10 
± 1.99e
-10
 
8 (n=10) 8.35e
10
±
 
4.87e
10
 81.54 ± 6.12 1.38e
-9 
± 8.56e
-10
 
9 (n=10) 1.22e
11
± 9.24e
10
 95.81 ± 11.71 1.95e
-9 
± 2.13e
-9
 
10 (n=10) 1.14e
11
± 7.81e
10
 99.59 ± 19.55 2.009e
- 9 
±  2.16e
-9
 
11 (n=10) 1.78e
11 
± 1.53e
11
 113.2 ± 6.99 4.11e
-9 
± 5.82e
-9
 
12 (n=10) 2.57e
11 
±  2.16e
11
 121.4 ± 15.94 9.68e
-10 
± 9.32e
-10
 
 
Data were presented as mean ± SD (range). CD63 was expressed in the number of exosome particle 
and PLAP was expressed in pg/ml. n=10 for each gestational week. 
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5.5 Plasma exosomal protein characterization in first trimester of pathological pregnancies  
Placenta derived exosomes increased in first trimester of pregnancy with gestational diabetes 
mellitus (GDM) and preeclampsia (PE) 
The cumulative number of combined exosomal population was quantified and placenta specific 
marker on exosomes (Placental Alkaline Phosphatase, PLAP) was measured in exosome rich 
sample from plasma collected during first trimester (11-14 weeks) complicated with gestational 
diabetes mellitus (n=7) using ELISA for specific exosomal endocytic marker CD63 and placenta 
specific marker PLAP respectively. The quantified total number of exosomes was 1.31e
12
 ± 1.60e
12
 
(mean ± SD) and the PLAP concentration was 171.7 ± 17.94 pg/ml. Also, the number of combined 
exosomal population counted in first trimester of preeclampsia (n=15) was 1.09e
11
 ± 3.17e
10
 
exosome vesicles/ ml of plasma and the PLAP concentration was 181.4 ± 28.37 pg/ml. 
Statistical analysis showed that the total number of exosomes released in first trimester of 
pregnancy complicated with GDM was three- fold higher than normal pregnancy (Figure 17A) and 
the exosomes released specifically from the placental cells was two- fold compared to PLAP 
concentration in uncomplicated pregnancy (Figure 17B). Also, the number of exosomes that was 
detected in first trimester of preeclampsia significantly increased (p<0.001) compared to first 
trimester of healthy pregnancy (Figure 18). Student’s t- test was performed to compare between 
normal healthy pregnancy (n =10) and preeclamptic (n =15) conditions. The total number of 
exosome particles in normal pregnancy was 1.33e
11
±1.27e
11 
(mean ± SD) and in preeclampsia was 
1.09e
11
 ± 3.17e
10
 (mean ± SD). 
Placenta derived exosomal contribution to total exosomes in GDM 
In order to know the contribution of placenta specific exosomes among combined exosome vesicles, 
ratio of PLAP and number of exosome particle (NEP) was calculated in GDM and was compared 
with uncomplicated pregnancies. The value of PLAP/NEP ratio was standardised as 1 in healthy 
pregnancy and approximately 64% reduction was observed in GDM (Figure 19). 
This outcome may reflect two possibilities; (i) placenta-derived exosomes in GDM are more 
reactive to increase the non-placental exosome release in maternal circulation (ii) the PLAP content 
is less expressed in GDM than normal pregnancy. 
The number of total exosome particle released into the peripheral circulation (CD63), amount of 
placenta specific exosomal marker (PLAP) and placental exosomal contribution to total exosomes 
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in the circulation (PLAP/CD63) in first trimester of normal pregnancy and gestational diabetes 
mellitus with ‘p’ values have been provided in Table VII. All data were presented as mean ± SD 
(range). CD63 was expressed in the number of exosome particle and PLAP was expressed in pg/ml. 
T test was performed to compare between normal pregnancy (n = 10) and gestational diabetes 
mellitus (n = 7) condition. The difference was statistically significant for CD63, PLAP and 
PLAP/CD63 in GDM compared to normal pregnancy with p<0.05, p<0.001 and p<0.001 
respectively. 
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A       B 
   
 
Figure 17. Placenta derived exosomes in maternal circulation during first trimester of normal 
uncomplicated pregnancy and gestational diabetes mellitus. Student’s t- test was performed to 
compare between normal healthy pregnancy (n =10) and gestational diabetes mellitus (n =7) 
conditions. The total number of exosome particles in normal pregnancy was 1.33e
11 
± 1.27e
11 
(mean 
± SD) and in GDM was 1.31e
12 
± 1.60e
12 
(mean ± SD). The measured exosomal PLAP 
concentration was 92.38 ± 22.89 pg/ml (mean ± SD) in normal pregnancy and 171.7 ± 17.94 pg/ml 
(mean ± SD) in GDM. The total number of exosomes in GDM was three- fold higher (p<0.05) than 
normal pregnancy (A) and the PLAP concentration (exosomes released from placental cells) was 
two- fold (p<0.001) compared to PLAP concentration in uncomplicated pregnancy (B). 
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Figure 18. Exosomal vesicle release in maternal circulation during first trimester of normal 
healthy pregnancy and in preeclampsia. Student’s t- test was performed to compare between 
normal healthy pregnancy (n =10) and preeclamptic (n =15) conditions. The total number of 
exosome particles in normal pregnancy was 1.33e
11 
± 1.27e
11 
(mean ± SD) and in preeclampsia was 
1.09e
11
 ± 3.17e
10
 (mean ± SD). The total number of exosomes in first trimester of pregnancy 
complicated with preeclampsia significantly increased (p<0.001) compared to healthy pregnancy. 
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Figure 19. Placenta derived exosomal contribution to total exosomes in GDM. Student’s t- test 
was performed to compare between normal healthy pregnancy (n =10) and gestational diabetes 
mellitus (n =7) conditions. PLAP/Number of Exosome Particle (NEP) in normal pregnancy was 
6.91e
-10 
± 5.11e
-11
 (mean ± SD) and in GDM was 2.53e
-10 
± 3.3e
-11 
(mean ± SD). PLAP 
concentration/Number of Exosome Particle ratio was standardised as 1 in normal healthy pregnancy 
and compared with GDM. Approximately 64% reduction (significance level, p<0.001) was 
observed in GDM. 
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Table VII. Comparison of number of exosome particle (CD63 & PLAP) in normal pregnancy vs 
gestational diabetes mellitus  
NEP Normal Pregnancy 
(n=10) 
Gestational Diabetes 
Mellitus (n=7)**** 
P Value 
CD63 1.33e
11 
± 1.27e
11
 1.31e
12 
± 1.60e
12
 < 0.05 
PLAP 92.38 ± 22.89 171.7 ± 17.94 < 0.001 
PLAP/CD63 6.91e
-10 
± 5.11e
-11
  2.53e
-10 
± 3.3e
-11
 < 0.001 
 
Data were presented as mean ± SD (range). CD63 was expressed in the number of exosome particle 
and PLAP was expressed in pg/ml. Student’s t- test was performed to compare between normal 
pregnancy and gestational diabetes mellitus condition. The difference was statistically significant 
for CD63, PLAP and PLAP/CD63 in GDM compared to normal pregnancy with p<0.05, p<0.001 
and p<0.001 respectively. 
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5.6 Mass spectrometry based proteomic profiling of plasma exosomes in first trimester of 
normal pregnancies 
All mass spectra were analyzed using MASCOT™ and Protein Pilot™ search engines against the 
Swissprot database with the species set as human, specifying trypsin as the enzyme. The MS/MS 
analysis of exosomal proteins in each gestational week of normal first trimester pregnancy (healthy 
uncomplicated pregnancy, n=10) have been provided in Table IX as an appendix. Approximately 
304 mass spectrometry identified exosomal proteins were detected in the plasma sample of women 
with normal pregnancy outcome (n=10) and 46 proteins in the plasma sample of control non-
pregnant women (n=5). The functional analysis of these exosomal proteins was performed using a 
bioinformatics tool - Ingenuity Pathway Analysis (IPA) software (Figure 20). Collectively 204 
canonical pathways regulated by these exosomal proteins (identified in first trimester of normal 
healthy pregnancy) were detected in Ingenuity Pathway Analysis. Of these 204 pathways, the 
activity of 113 canonical pathways was upregulated and downregulated for 91 pathways with the 
advancement of pregnancy from 6-12 weeks. A linear correlation was observed in between the 
pathway activation and the gestational age in all these pathways. Of these pathways, some pathways 
were associated with immune responses during pregnancy (assessed by functional analysis in IPA). 
The arbitrary scores in these pathways were estimated using IPA core, tox & comparison Analysis. 
The scores were calculated depending on the potential capability of the proteins to activate the 
specific immune response pathway in each gestational week. The identity of those pathways with 
their scores in each gestational week has been provided in Table VIII. The LC-MS/MS detected 
proteins were further analysed using another bioinformatics tool - PANTHER (www.pantherdb.org) 
software. The varied functions of the exosomal proteins in plasma of normal healthy pregnant 
women have been illustrated in the Venn diagrams (Figure 21). Comparative analysis of immune 
responses activated by the exosomal proteins identified in normal healthy pregnant women and in 
control non-pregnant women was performed using PANTHER gene analysis (Figure 22). It was 
observed that immune responses were more specific in pregnant women compared to non-pregnant 
women displaying additional immunological functions i.e. antigen processing and presentation, 
macrophage activation. 
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Figure 20. Comparative analysis of mass spectrometry detected exosomal proteins assessed in 
Ingenuity Pathway Analysis (IPA) bioinformatics tool. In Venn diagram, (A) 304 proteins were 
identified in the plasma sample of normal healthy pregnant women (n=10), (B) 46 proteins were 
identified in the plasma of control non-pregnant women (n=5). 
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Table VIII. Canonical pathways associated with immune responses with arbitrary scores in first 
trimester (6-12 weeks) of normal healthy pregnancy 
Canonical 
Pathway 
Scores in Gestational Weeks 
 6 week 7 week 8 week 9 week 10 week 11 week 12 week 
Acute Phase 
Respose 
Signalling 
5.93 6.64 6.92 6.94 7.30 7.84 9.17 
Primary 
Immunodeficiency 
Signalling 
2.06 5.87 6.04 5.32 4.40 5.95 5.84 
B Cell 
Development 
1.56 2.88 2.97 3.32 1.64 2.93 3.63 
IL-12 Signalling 
and Production of 
Macrophages 
1.02 1.88 0.68 1.57 1.11 1.93 1.85 
Production of 
Nitric Oxide and 
Reactive Oxygen 
Species in 
Macrophages 
0.75 2.12 0.504 1.26 0.83 1.52 1.53 
IL-6 Signaling 0.62 0.26 1.43 1.74 0.29 0.75 1.15 
 
The scores were arbitrary which were estimated using IPA (Ingenuity Pathway Analysis 
bioinformatics tool) Core, Tox & Comparison Analysis. The scores were based on the potential 
capability of the proteins to activate the specific immune response pathway.  
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Figure 21. Different biological functions of LC-MS/MS detected exosomal proteins in 
maternal circulation using PANTHER bioinformatics tool. Different colours in the Venn 
diagram represent different biological functions of the proteins identified in plasma exosomes 
during first trimester (6-12 weeks) of normal healthy pregnant women (n=10). 
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             Pregnant (n=10)           Non-pregnant (n=5) 
 
Figure 22. Comparative analysis of immune responses activated by the exosomal proteins 
identified in plasma of normal healthy pregnant women and control non-pregnant women 
using PANTHER gene analysis. Different colours in the Venn diagram represent different 
immunological functions. (A) Immunological functions of exosomal proteins in the plasma of 
normal healthy pregnant women (n=10) during first trimester (6-12 weeks) & (B) Immunological 
functions of exosomal proteins in the plasma of control non-pregnant women (n=5).   
  
antigen processing and presentation 
immune response 
macrophage activation 
Results  
 
 
 
- 66 - 
 
5.7 Mass spectrometry based proteomic profiling of plasma exosomes in first trimester of 
pathological pregnancies 
10 µg of exosomal protein from plasma of preeclamptic condition (n=1) during first trimester (11-
14 weeks) was processed for mass spectrometric proteomic analysis. The mass spectra were 
analysed using the protein pilot software specifying paragon method in swissprot database search 
engine setting the species as human and specifying the trypsin enzyme. 25 proteins were identified 
in preeclamptic condition (n=1).  The proteins were considered significant with the presence of 
peptide >1%. All these mass spectrometry detected exosomal proteins were inserted into the IPA 
(Ingenuity Pathway Analysis) bioinformatics tool. 35 canonical pathways were detected in IPA 
core, tox and metabolomics analysis. Haematopoiesis, primary immunodeficiency signalling, acute 
phase response, B cell development, coagulation system signalling were the important pathways 
that were activated with these proteins (Figure 23). Some diseases and toxicity functions were 
identified that were associated with these proteins i.e. immunological diseases, cardiotoxicity, 
hepatotoxicity, nephrotoxicity (Figure 24). 
Comparative analysis of plasma exosomal peptide profile in normal pregnancy and 
preeclampsia 
10 µg of protein in exosome enriched sample from plasma of preeclamptic condition (n=1) and 
normal healthy pregnancy (n=1) during first trimester was processed for mass spectrometric 
proteomic analysis. The mass spectra were analysed using the protein pilot software specifying 
paragon method in swissprot database search engine setting the species as human and specifying the 
trypsin enzyme. 40 proteins were identified in first trimester of normal pregnancy condition (n=1) 
and 25 in preeclamptic condition (n=1). The proteins were considered significant with the presence 
of peptide >1%. 10 similar proteins were detected in both conditions (Figure 25). Among all these 
proteins, fibronectin or galectin-3 binding proteins were not observed in first trimester preeclamptic 
maternal plasma exosomal sample which were evident in first trimester normal healthy pregnant 
women’s plasma exosomal sample. These proteins indicate normal placental function to maintain 
the pregnancy successfully. However, these discrepancies in exosomal proteins were observed in a 
single set of sample that needs to be verified for other samples and further study needs to be 
conducted where a large group of patients can be recruited. 
These proteins were entered into the IPA (Ingenuity Pathway Analysis) bioinformatics tool. A 
comparison analysis between these two conditions was performed using the IPA core, tox and 
metabolomics analysis. The comparison was made on the basis of canonical pathways regulated by 
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the proteins in these conditions. Primary immunodeficiency signalling, haematopoiesis and B cell 
development were more activated with the proteins of preeclamptic condition compared to proteins 
of normal pregnancy condition. On the contrary, acute immune response pathway was potentiated 
with the proteins of normal pregnancy condition rather than preeclamptic condition (Figure 26). 
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Figure 23. Canonical pathways using IPA bioinformatics tool for exosomal proteins identified 
in first trimester (11-14 weeks)  preeclamptic women’s (n=1) plasma sample. Haematopoiesis 
from pluripotent stem cells, primary immunodeficiency signalling, acute phase response signalling, 
B cell development, coagulation system were the top canonical pathways that were activated with 
the exosomal proteins identified in LC-MS/MS analysis. 
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Figure 24. Diseases and toxicity functions of exosomal proteins identified in first trimester of preeclamptic 
condition (n=1) using Ingenuity Pathway Analysis bioinformatics tool. The mass spectrometry identified 
exosomal proteins in plasma of first trimester preeclamptic condition that were associated with different diseases 
and disorders, molecular and cellular functions, physiological system development and several toxicity functions. 
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                                        n=1                        n=1 
Figure 25. LC-MS/MS detected exosomal proteins from plasma in first trimester of normal 
pregnancy and preeclampsia. Comparison was made using Ingenuity Pathway Analysis (IPA) 
core, tox and metabolomics analysis. 30 proteins were identified in normal healthy pregnancy (n=1) 
and 15 proteins in preeclampsia (n=1). 10 similar proteins were detected in normal pregnancy and 
preeclampsia. 
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Figure 26. Activated canonical pathways in normal healthy pregnancy and preeclampsia 
using Ingenuity Pathway Analysis bioinformatics software.  Primary immunodeficiency 
signalling, haematopoiesis and B cell development were significantly activated with the exosomal 
proteins identified in preeclamptic condition compared to normal pregnancy. Acute immune 
response pathway was potentiated with the exosomal proteins of normal pregnancy condition than 
preeclamptic condition. 
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CHAPTER VI 
6. DISCUSSION 
Currently, there are no proven means of identifying presymptomatic women who subsequently 
develop complications during early pregnancy. Most women who are triaged into high-risk clinical 
units on the basis of poor previous obstetric history ultimately have uncomplicated pregnancies. 
Early detection of women at risk of pregnancy complications would provide an opportunity to 
develop and evaluate timely and appropriate intervention strategies to limit acute adverse sequelae. 
The rationale for developing early pregnancy screening tests is not only for the management of the 
contemporaneous pregnancy but also to optimise lifelong and intergenerational health. Recent 
studies highlight the putative utility of tissue-specific nanovesicles (i.e. exosomes) in the diagnosis 
of disease onset and treatment monitoring; however, the exosome profile in early pregnancy (i.e. 
from 6 to 12 weeks) remains to be established. The overall aim of this study was to characterise 
gestational age associated variation in the concentration of placenta-derived exosomes in maternal 
plasma during first trimester of pregnancy from women with normal pregnancies (without any 
complication across pregnancy) and pre-symptomatic women who subsequently developed 
gestational diabetes mellitus (GDM) and preeclampsia (PE), pathologies that were diagnosed in the 
second trimester. Weekly serial blood samples (from 6 to 12 weeks) were collected and exosomes 
were isolated and characterised. The results showed that the number of exosomes vesicles present in 
maternal plasma increased progressively during first trimester, as did exosomal PLAP (placental 
marker) concentration in healthy women with normal pregnancy outcome. Patients who developed 
GDM and PE in the second trimester of pregnancy, exhibited higher amount in the number of 
exosomes and exosomal PLAP in the first trimester compared to healthy controls. Finally, using a 
mass spectrometry approach exosomal protein changes in patients with GDM and PE were 
attempted to identify. These results suggest that exosomes from placenta could potentially be used 
as surrogate diagnostic markers for placental function, extending its utility to screen asymptomatic 
population. 
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6.1 Exosomes isolation from maternal plasma 
The purification of exosomes from plasma and other biological fluids is not trivial. Exosomes have 
been isolated from many different biological fluids with success and these procedures were largely 
developed using principally supernatants of cultured cells and plasma. In this study, exosomes were 
isolated from maternal plasma by differential and buoyant density centrifugation using a sucrose 
continuous gradient [103, 104]. In this regard, a straightforward method was utilised to estimate the 
number of exosomal vesicles that were obtained after the sucrose continuous gradient purification. 
An automatic system was used to collect the fractions after preparing a sucrose continuous gradient 
on the top of isolated exosomal sample dissolved in 2.5 M sucrose stock solution enables a highly 
reproducible density and decreasing the coefficient of variation between samples. In addition, using 
purification method based on the density of exosomes, vesicles were discarded with the same size 
of exosomes but not from endosomal origin (indicates high purity). 
On the other hand, samples used in this study were kindly provided by Professor Sebastian Illanes 
(MD, Obstetrics and Gynaecology specialist) from Clinica DAVILA (Santiago, Chile). Serial blood 
samples were collected from pregnant women and plasma samples were separated from whole 
blood and stored at -80 
0
C until they were sent to UQCCR (Brisbane, Australia, within 4 weeks of 
collection). In order to discard any differences attributed to the freeze thaw cycle during exosomes 
isolation, their stability was determined using fresh and frozen plasma. In this study it was 
established that exosomes were very stable when stored at -80
o
C.  Similar number of exosomes 
yield from fresh and stored samples (i.e. plasma) were obtained and the gestational age differences 
in plasma exosomes number was identified in long-term stored samples. The isolation of exosomes 
from stored biofluids is quite normal rather than the exception. These results are consistent with 
those of other studies [105, 106] and suggest that the exosomal contents are protected inside these 
vesicles, highlighting the potential use of exosomes as biomarker based on their stability under 
different conditions.     
To test biologic activities of plasma-derived exosomes, methods are necessary that ensure adequate 
recovery of exosome fractions free of contaminating larger vesicles, cell fragments and 
protein/nucleic acid aggregates. Exosome vesicles were isolated using the gold standard method of 
differential ultracentrifugation and filtration followed by sucrose gradient purification from 
maternal plasma sample [104]. The amount of protein was estimated in initial plasma sample, 
samples collected after different stages of differential centrifugation and also in purified samples. 
The measured protein concentration revealed gradual diminution over the isolation steps indicating 
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removal of cellular debris, apoptotic bodies, microparticles, highly abundant plasma proteins 
yielding exosome pure sample. There was ~10-fold reduction in the amount of total proteins 
compared to initial plasma sample following differential ultracentrifugation. The total protein 
concentration reduced significantly in all three purification (mentioned above) steps compared to 
ultracentrifugation simply. These isolated nanovesicles using these methods, displayed a diameter 
between 30-100 nm under transmission electron microscopic (TEM) analysis and their size 
distribution showed in the range of 30-150 nm with the majority (>95%) being 74 nm in the 
nanoparticle tracking analysis (NTA). Others studies have used flow cytometer to detect the size of 
the vesicles [31, 107]; however, this methodology cannot detect the smaller vesicles (i.e. 
exosomes). NTA can determine vesicle’s size using the Brownian motion by tracking, visualizing 
and quantifying nanoparticles down to 50 nm.   Exosomal population in the derived sample was 
further enriched by sucrose density gradient (1.11-1.19 g/ml) centrifugation. All these 
morphological characteristics are consistent with the exosomal characteristics that were evident in 
the previously published data [47, 108]. 
6.2 Placental-derived exosomes in maternal circulation 
Exosomes are released from many different cell types, including the human placenta. 
Syncytiotrophoblast (more abundant cell type in the human placenta) constitutively release vesicles 
during normal pregnancy. Recently, it was established that normal pregnancy is associated with the 
increase in exosomes release into maternal plasma, and placenta-derived exosomes concentration 
increases a further 6-fold during uncomplicated healthy pregnancy from first to third trimester 
[103]. There is substantial evidence that these placental-derived exosomes are taken up by different 
cells in the maternal circulation and alter their phenotype [3, 109] In addition, it was found that the 
content of these released exosomes are placenta-specific [83], converting the study of these 
microvesicles in an excellent tool for the understanding of different physiological processes 
occurring during embryo/fetal development and the feto maternal interaction.  
It has been established that the concentration of exosomes in maternal peripheral blood is greater 
than that observed in non-pregnant women [110]. In this study, exosomes of placental origin were 
specifically isolated from the maternal blood using anti-PLAP (anti-placental-type alkaline 
phosphatase) conjugated to agarose micro-beads. Studies completed to date provide persuasive 
evidence that placental cell-derived exosomes play a significant role in intercellular communication 
pathways that potentially contribute to placentation and development of maternal-fetal vascular 
exchange. 
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As exosomes carry different kinds of protein, mRNA and miRNA [69], engaging in cell-to-cell 
communication, it is likely that they play an important role in modifying the maternal physiological 
state to maintain a successful pregnancy [111]. Interestingly, in this study it was found that 
placental-derived exosomes increased systematically during the first trimester as early as sixth week 
of pregnancy when the intervillous circulation is not fully established. However, it has been 
observed that communication between placental and fetal circulation occurs at the beginning of the 
fourth week of post conception [112]. Moreover, the lacunar spaces are formed in the trophoblast 
from as early as nine days of post-ovulation and maternal blood flows into the trophoblast lacunae 
between ten and eleven days after fecundation. In addition, it has been reported that the intervillous 
blood flow is present in an early stage (i.e. < seventh week) [113] and increases gradually from 
fourth week during the first trimester of pregnancy [114]. 
Trophoblast plugs occlude the spiral arteries to prevent the contact of maternal blood flow into the 
intervillous space, however, at the same time trophoblast plug are in contact with the maternal 
blood, and could release soluble proteins (e.g. human chorionic gonadotropin, hCG) and vesicles 
(e.g. nanovesicles) into maternal circulation. It is interesting to highlight that hCG can be measured 
in maternal plasma as early as 4 weeks of gestation, confirming the presence of molecules released 
from the trophoblast in early pregnancy. Moreover, β-hCG and pregnancy-associated plasma 
protein A (PAPP-A) have been measured in maternal plasma as early as 6 weeks of gestation [115]. 
Recently, the exosome profile across pregnancy has been published. The concentration of total 
exosomes increased during normal gestation from first to third trimester. Moreover, the release of 
placenta-derived exosomes increased with the gestational age and displayed a positive correlation 
with the placental mass at third trimester of normal pregnancy [116]. However, the exosomal 
content with their potential different functions across gestation remains to be established. In terms 
of the function of these placental exosomes, Mincheva-Nilsson et al. [74, 117] have already 
published a series of manuscripts describing the role of exosomes as immunosuppressive agent 
regulating maternal immunity in several ways. 
In regards to the clearance of placental exosomes from maternal circulation after delivery, Luo et al. 
[118] demonstrated by real-time PCR, the rapid clearance of the placenta-specific exosomal 
miRNAs after 3 days of delivery. The placental exosome profile during the first 24 hours of post-
delivery has not been established yet. 
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Furthermore, there is robust evidence that these exosomes play significant role in pregnancy 
complications, especially in PE. Different studies demonstrated that extracellular vesicles (including 
exosomes) originating from placental explant and placental cells cause endothelial dysfunction 
[119, 120] and promote pro-inflammatory cytokines production [121]. Using a placental marker 
(i.e. Placental Alkaline Phosphatase, PLAP), placenta-derived vesicles was discovered in maternal 
plasma from first trimester of pregnancy [119, 121]. In this study, immunoreactive exosomal PLAP 
was not detectable in plasma of non-pregnant women, supporting previously conducted studies by 
other group [31, 90, 122]. In another study it was identified that placental cytotrophoblasts derived 
exosomes carry syncytin proteins that were responsible for increased cellular uptake and fusion to 
form the syncytiotrophoblast cells and contribute to proper establishment of uteroplacental 
circulation during pregnancy. However, this syncytin protein was less abundant in pregnant 
women’s circulation who developed preeclampsia compared to those who went through 
uncomplicated pregnancies [76]. 
On the contrary, overall exosome number as well as placenta derived exosomes displayed a 
significant increase in maternal circulation during first trimester in both GDM and PE condition 
compared to normal pregnant state which is quite similar to results that were observed by other 
group [71, 120, 123, 124]. However, the contribution of specific placenta derived exosomes to 
cumulative exosomal population which was measured as PLAP/exosome number did not show 
significant variation in different gestational weeks in first trimester though this ratio showed 
significant reduction compared to that of normal healthy pregnancy condition. This result indicates 
that in pathological pregnancy, the specific placental-derived exosomes do not increase like total 
exosome population compared to healthy pregnancy. Therefore, it can be assumed that exosomes 
from placental origin are more reactive to other cells (i.e. endothelial cells, cells of immune system, 
platelets) which release exosomes and attribute to increase in overall exosome number. This 
noticeable finding is consistent to previously conducted studies [125-128]. 
6.3 Exosomal protein content and potential functions 
Recently, several attempts and techniques were undertaken to determine and characterize the 
exosomal content in different biological fluids including normal human blood plasma  As exosomes 
carry different kinds of protein molecules [69] and engage in cell to cell communication, it is likely 
that they play an important role in modifying the maternal physiological state to maintain the 
pregnancy successfully [111]. In this study, plasma exosomal proteomic profile was further 
elucidated by mass spectrometric analysis of protein biomarkers that were associated with the 
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physiological changes in pregnancy. Some exosomal complex proteins, pregnancy associated 
proteins, fibronectin, galectin-3 binding protein were identified in first trimester maternal plasma 
samples following numerous steps of isolation and purification of exosomes. All these proteins 
were evident in maternal circulation during first trimester in other placental exosome research 
studies [132] that indicate normal maternal physiological and placental function during healthy 
uncomplicated pregnancy.  304 different proteins were identified in 6-12 gestational weeks (n=10 in 
each gestational age) and in bioinformatics analysis, 6 canonical pathways were detected that were 
regulated by these proteins and displayed association with different immunological functions that 
may be of utility in providing a stable immune tolerance during pregnancy to prevent the fetal 
allograft rejection. 
Exosome analysis provides diagnostic and therapeutic potential and biomarker opportunities for the 
early detection of diseases [91, 133, 134]. To date, several research studies have been performed to 
identify the morphologic and proteomic characteristics of exosomes [71] released from the placental 
extravillous trophoblastic cells and expression profile of these exosomal contents related to 
common pregnancy conditions [6, 73, 135].  
Exosomal marker molecules such as MHC class I chain related antigens A and B were observed to 
be expressed in exosomes from syncytiotrophoblast during pregnancy [72]. Several studies have 
observed the effect of nanovesicles secreted from syncytiotrophoblast (PLAP
+
) on endothelial cell, 
producing endothelial cell dysfunction through inhibition of their proliferation [119, 136, 137]. 
Moreover, many studies found different proteins (i.e. Flt-1, Endoglin, IL-1β, TFPI, CD81, Alix, 
cytoskeleton related proteins, Rab family of proteins) incorporated in nanovesicles shedding from 
placental syncytiotrophoblast cells in preeclampsia even in first trimester that can alter vascular 
endothelial cell function [6, 135, 138, 139]. 
In conclusion, placental microenvironment plays an important role during normal healthy 
pregnancy as well as in pathological pregnancy to determine the pattern of release and packaging of 
components (i.e. proteins) of the nanovesicles shedding from the placental cells that has been 
evidenced as early as in first trimester. Nevertheless, the sequelae of these pregnancy complications 
are the consequences of cellular interaction in maternal peripheral circulation by these placenta 
derived nanovesicles containing specific proteins. These ideas support this study to investigate the 
proteomic profile of nanovesicles in maternal plasma with manifestation of common pregnancy 
pathologies in the period of first trimester (early pregnancy). 
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6.4 Exosomes as potential biomarker of placental function 
Previous studies have established that extracellular vesicles, including exosomes are released under 
normal physiological and pathophysiological conditions, and it has also been observed that 
exosome release is negligible in non-pregnant women’s circulation compared to healthy normal 
pregnant women [92]. During gestation the release of these vesicles is increased and also in 
response to different pathological conditions [140]; presumably due to exosomal secretion from 
placental trophoblastic cells to the maternal peripheral circulation [71, 92]. However, all these 
studies considered the late second or third trimester of pregnancy plasma samples for analysis 
though provide valuable insights about the possibility of conducting this research in early 
pregnancy. 
The total number of exosome vesicles is significantly increased in maternal circulation during 
pregnancy. The placenta derived exosomes are also increased in the circulation along with the 
advancing gestational age. In addition, exosomes isolated from maternal circulation during normal 
pregnancy exhibit changes in their bioactivity. Nanovesicles from first trimester of pregnancy were 
more bioactive in promoting endothelial cell migration than the vesicles isolated in second and third 
trimester. The effect of these nanovesicles could be associated with the cellular origin and/or 
exosomal content (e.g. proteins) which forecast the placental function in early normal pregnancy 
and could be potentially important to determine the disordered placentation in complicated 
pregnancies [90]. It has been demonstrated that exosomal protein content is different in women with 
preeclampsia [141]. Moreover, the specific syncytiotrophoblast protein, syncytin-2, is markedly 
down-regulated in exosomes derived from placenta of pregnant women with preeclampsia 
compared to healthy control (normal pregnancies) [94]. 
In this study, specific placental-derived exosomes were quantified in the maternal circulation using 
the immunoreactive placental protein PLAP. Recent studies have demonstrated the presence of 
exosomes- PLAP (+ve) only in peripheral circulation of pregnant women [90, 92]. PLAP is an 
integral membrane protein (enzyme) unique to the placenta (it has also been observed in some 
gynaecologic cancers), produced mainly by syncytiotrophoblast [142, 143]. Nevertheless, PLAP 
expression has been found in primary trophoblast cytotrophoblast cells [90] and ED27 trophoblast-
like cells, both isolated from first trimester chorionic villi, and also in JEG-3 cells (a extravillous 
trophoblast model) [144]. In addition, using immunohistochemistry stain for PLAP, the majority of 
chorionic trophoblastic cells were positive for PLAP [145]. During the first trimester of pregnancy, 
the release of placental exosomes into the maternal blood may result from extravillous trophoblast 
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and/or syncytiotrophoblast cells; however, while a definitive answer awaits further investigation, it 
is of relevance to note that fetal cells are present in maternal blood from 4 weeks of pregnancy and 
that trophoblast cells invade the decidua and myometrium from the time of implantation. Thus, 
placental cellular and exosomal pathway exists for delivery into the maternal circulation. 
Cell to cell communication via these exosomes in placental microenvironment is the platform for 
organisation of placental interface that provide fetal immune tolerance, protection against several 
viral infection and lastly potentiate cell fusion which is required for syncytiotrophoblast formation 
for the maternal-fetal communication during pregnancy [75]. In maternal peripheral circulation, 
exosomes derived from placental villous trophoblasts contain specific proteins such as syncytin-1 
and syncytin-2. These protein act as mediators for the fusion, formation and maintenance of 
cytotrophoblast to syncytiotrophoblast in early pregnancy, which is essential for placentation to 
ensure optimum nutrient and oxygen levels as well as adequate immunosuppression for the 
developing fetus [94]. In addition, exosomal syncytin-1 derived from placental trophoblastic cells 
inhibited the production of cytokines (i.e. TNF-α and IFN-γ) by T lymphocyte. This inhibitory 
response of these exosomes during pregnancy could play imperative role in the maternal immune 
tolerance [146, 147]. 
On the other hand, placental exosomes carry specific miRNAs coming from placental cells that has 
been detected in maternal peripheral circulation [148]. During pregnancy placenta acts as a shield to 
protect the embryo from different pathogens. A distinctive type of miRNA has been identified and 
detected in higher concentration in maternal peripheral circulation during pregnancy that is 
packaged within the trophoblast-derived exosomes, which provide the resistance from many viral 
infections by local and/or systemic function [149, 150]. 
Complications of pregnancies are associated with hypoxia and poor placentation. Using primary 
trophoblastic cells, it has been demonstrated that exosome release and their protein content are very 
sensitive to the microenvironment milieu (i.e. oxygen tension, hyperglycaemia etc.) [3, 71, 109, 
151, 152]. As such, the concentration, content and/or bioactivity of placenta-derived exosomes in 
maternal plasma may be informative of placental dysfunction. Altogether, the results of this study 
and previously published data show that in normal pregnancies, the concentration, protein content 
and bioactivity of placenta-derived exosomes in maternal plasma varied significantly with 
gestational age. These observations are consistent with the hypothesis that exosomes are released 
from the placenta during early pregnancy into maternal blood and may play a role in the maternal 
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adaptation to pregnancy. Gestational age related changes in the profile and characteristics of 
exosomes in maternal blood may be of clinical utility in the diagnosis of placental dysfunction. 
 
6.5 Final remarks 
The data obtained in this study establish that pregnancy is associated with a significant increase in 
the number of exosomes circulating in maternal blood due to the increased release from the placenta 
that varies with different gestational age in terms of their different characterisation and proteomic 
profiling. Available evidence supports the hypothesis that the aetiology of pregnancy complications 
begins during first trimester. If this is the case, then changes in the profile of placenta-derived 
biomarkers during early pregnancy may be common to and characteristic of, women at risk of 
developing complications of pregnancy. Identification of such molecules would provide an 
opportunity to develop clinically useful early pregnancy screening tests to identify those 
asymptomatic women who develop the common pathologies (GDM, PE) during pregnancy. If this 
can be achieved it will provide an opportunity for early assessment of risk and the implementation 
of an alternative clinical management strategy to improve outcome for both mother and baby. 
Finally, in this study it was clearly established that overall exosome release is augmented during 
pregnancy that ensues as early as 6 weeks of pregnancy and exhibits increase in incremental manner 
with the progression of pregnancy. This increase was actually due to the boosted secretion of 
exosomes particularly from placental cells. However, in pregnancy pathologies (i.e. PE and GDM), 
both the total exosome number and placenta derived exosome showed significant increase 
compared to normal healthy pregnant state. In addition, the mass spectrometric proteomic study 
identified some plasma exosomal proteins in normal pregnant condition that are closely related with 
the pregnancy physiological processes whereas those were not evident in pathological pregnancy 
conditions. 
6.6 Limitations 
This study is based on utilising plasma sample from pregnant women. Plasma is a type of sample 
that contains a wide variety of plasma proteins, different hormones and tissue factors. Therefore, 
isolating exosomes with purity in higher concentration from plasma is a challenge. Additionally, 
exosomes in maternal circulation is mixed up of exosomes originating from different cellular 
sources. As this study considered pregnancy related conditions, it was important as well as 
challenging to separate the exosomes that are released specifically from placental trophoblast cells. 
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Another challenge was to remove contaminants from the exosomes to identify the protein contents 
of the exosomes in mass spectrometric proteomic study. However, all these difficulties were 
surpassed by using high- throughput technologies, i.e. mass spectrometry based proteomic studies. 
 
6.7 Future directions 
Persuasive evidence of specific exosomal protein in maternal peripheral circulation with pregnancy 
pathologies (i.e. GDM, PE) in first trimester of pregnancy would contribute to discover a panel of 
biomarkers associated with these complications. It is important to develop novel technique and 
approach that would monitor the fluctuation (i.e. increase, decrease) of these candidate protein 
biomarkers in maternal circulation. Subsequently there would be an avenue to develop screening 
tests utilising these potential biomarkers in early gestational period that can be further applied on 
pregnant women during antenatal visits as clinical trial to screen asymptomatic population who 
might develop pregnancy complications in their late second or third trimester of gestation. 
Therefore, conducting further exosomal proteomic studies using plasma sample of pathological 
pregnancies is of great value that would lead to proper direction of this pregnancy exosome 
research.
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CHAPTER VII 
7. CONCLUSIONS 
 
7.1 Conclusions 
The main purpose of this MPhil thesis was to identify blood-borne biomarkers (i.e. exosomes) that 
may be used in the first trimester of pregnancy to identify presymptomatic women who are at risk 
of developing complications of pregnancy at later stage of gestation. A time-series experimental 
design was used to establish pregnancy-associated changes in maternal plasma exosome 
concentrations during the first trimester. Four groups of women were involved in this study (normal 
healthy pregnant women, n=10; preeclamptic women, n=15; gestational diabetic women, n=7 and 
non-pregnant women, n=5). This study initially investigated the amount of circulating exosomes in 
healthy pregnant women during their first trimester. Further, the change in exosomal release with 
the progression of pregnancy was detected. The origin of these released exosomes was examined to 
see whether these were coming from the placenta. Afterwards, the ratio of the contribution of these 
placenta derived exosomes to the total exosomal population was measured. All these analyses were 
also conducted in pathological pregnancies (i.e. preeclampsia and gestational diabetes mellitus) in 
the first trimester samples. Preliminary studies were performed to identify exosomal protein 
contents from a small sample size in normal healthy pregnancies and complicated pregnancies. 
The results were derived from overall and placenta specific exosomal release in maternal circulation 
as quantified by ELISA. For the first time, this study observed that a significant number of 
exosomes released in maternal blood circulation during pregnancy and the cumulative population of 
these exsosome vesicles increased from as early as 6 weeks of pregnancy. This exosomal release 
increased in incremental manner with the progression of pregnancy which was actually due to the 
enhanced secretion of exosomes particularly from the placental cells. In addition, it was noticed that 
the total and placenta derived exosomes varied with different gestational ages in terms of their 
different characterisation and proteomic profiling.  
This study also found that women who developed pregnancy complications such as preeclampsia 
(PE) and gestational diabetes mellitus (GDM) displayed altered exosome concentration in the first 
trimester compared to healthy pregnant women. It is important to note that in pregnancy pathologies 
the total exosome number and placenta derived exosomes equally showed substantial increase 
compared to normal healthy pregnant state. This substantial increase is considered to be due to 
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abnormalities in the maternal circulatory environment (low oxygen tension in PE and high blood 
glucose level with insulin resistance in GDM) that act upon placental and other immune cells to 
favour the release of exosomes. Another noticeable finding was the ratio of placental derived 
exosomes to total exosomes in GDM which was lower compared to normal uncomplicated 
pregnancies. This outcome may reflect two possibilities; (i) placenta-derived exosomes in GDM are 
more reactive to increase the non-placental exosomal release in maternal circulation and/or (ii) the 
PLAP (placenta specific marker on exosomes) content is less expressed in GDM than normal 
pregnancy. 
The preliminary mass spectrometry based proteomic studies identified some plasma exosomal 
proteins in normal pregnancies but not in pathological pregnancies.  The identified proteins were 
fibronectin and galectin-3 binding protein. They are considered to be intimately related with the 
pregnancy associated maternal systemic changes (i.e. immunosuppression during pregnancy). These 
results are found to be consistent with other related studies. Their absence in preeclamptic plasma 
exosomal proteins may reveal aberrant maternal adaptation to changes in pregnancy complicated 
with preeclampsia. However, further studies are essential to validate these findings. 
 
7.2 Significance of findings 
To date, no study has been conducted in the arena of pregnancy exosome research in early 
pregnancy (i.e. first trimester). This area is still burgeoning. This study attempted to present the 
relationship between the release of exosomes in maternal circulatory system and the pregnancy 
related physiological changes in very early pregnancy. The significance of this study is to recognise 
the asymptomatic pregnant women in very early pregnancy (i.e. first trimester) that may develop 
pregnancy complications later.  
The observation of altered concentration of exosome vesicles and/or the exosomal protein 
composition associated with pathological pregnancies can be utilised in the clinical implications i.e. 
in the diagnosis of placental dysfunction. Recently several research studies focussed the 
significance of utilising tissue-specific nanovesicles (e.g. exosomes) in the diagnosis of different 
disease diagnosis and prognosis after delivering treatment. Additionally, the exosomal release in 
plasma has been reported to be altered in relation to disease severity and/or progression.  
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This study establishes exosomal profile associated with the normal healthy pregnancy state as well 
as in some common pathological conditions of pregnancy i.e. preeclampsia and gestational diabetes 
mellitus. The currently available data from this study would contribute in the identification of 
reliable exosome based biomarkers in maternal blood. These exosomal biomarkers may be of utility 
in developing a classification model where different pregnancy conditions would be categorised 
depending on the presence or absence including fluctuation in concentration of specific exosomal 
biomarker. Eventually, the classification model can be utilised to generate antenatal screening tests 
of high sensitivity and specificity.  
The ultimate goal is to screen pregnant mothers using the antenatal screening tests in their first 
trimester when they are asymptomatic but may develop preeclampsia or gestational diabetes in the 
late second or third trimester. This concept of screening is important for early therapeutic 
intervention and prevention of maternal and fetal complications arising from the common 
pregnancy complications before the manifestation of clinical signs. 
 
7.3 Recommendations for future research 
The presented work has identified many challenges regarding the methods of exosome vesicle 
isolation, characterisation, proteomic profiling and development of exosome based biomarkers. This 
requires further studies and specific suggestions regarding this are described below: 
Firstly, this study was based on utilising plasma sample from pregnant women. Plasma is a type of 
sample that contains a wide variety of plasma proteins, different hormones and tissue factors. 
Therefore, isolating pure exosomes in higher concentration from plasma is a challenge. In order to 
yield pure exosome vesicles in increased concentration from plasma, the methods of exosome 
isolation need to be reviewed and further improved. This can be achieved by considering the 
application of optimum centrifugation force and time as well as selection of proper 
ultracentrifugation bucket and rotor. Secondly, exosomes in maternal circulation is mixed up of 
exosomes originating from different cellular sources. As this study considered pregnancy related 
conditions, it was important as well as challenging to separate the placenta specific exosomes. 
Novel techniques need to be developed to isolate the exosomes of specific interest that may be done 
by using magnetic beads or by immunoaffinity based isolation. Thirdly, exosomal characterisation 
methods need to be further advanced by using immunoblotting and nanoparticle tracking analysis. 
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Another challenge was to remove the contaminants and highly abundant plasma proteins from the 
exosomes to identify the specific exosomal protein contents in mass spectrometry based proteomic 
study. In order to surpass these difficulties, mass spectrometry based technologies have to be well 
developed which can be obtained by using some different methods of removal of highly abundant 
plasma proteins (i.e. albumin, fibrinogen, prothrombin etc.) as well as contaminants (i.e. keratin). 
Additionally, in order to retrieve specific exosomal proteins with accuracy offgel fractionation 
method can be followed. On the other hand, to discover the exosome based biomarkers related with 
different pregnancy conditions, a large group of patients with different ethnic background need to 
be recruited and further study need to be conducted. It is important to discover a panel of 
biomarkers with greater predictive value which also necessitates further research. This can be 
achieved by analysing various sets of samples to detect the individual variability between groups 
and also to identify commonly appearing proteins. Finally, the available proteomic approaches and 
methods to identify the biomarkers need to be robust as well as cost-effective to introduce in 
clinical setting. 
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Appendix A: List of exosomal proteins in first trimester of pregnancy 
Table IX. Mass spectrometry detected exosomal proteins in first trimester of normal healthy 
pregnancy 
 
6 week (n=10) 
 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_H
UMAN 
A2M alpha-2-macroglobulin Extracellul
ar Space 
transporter 
GABT_HU
MAN 
ABAT 4-aminobutyrate aminotransferase Cytoplasm enzyme 
ACACA_H
UMAN 
ACACA acetyl-CoA carboxylase alpha Cytoplasm enzyme 
ACTA_HU
MAN 
ACTA2 actin, alpha 2, smooth muscle, aorta Cytoplasm other 
ADAL_HU
MAN 
ADAL adenosine deaminase-like Cytoplasm enzyme 
ATS9_HU
MAN 
ADAM
TS9 
ADAM metallopeptidase with thrombospondin type 1 motif, 9 Extracellul
ar Space 
peptidase 
KFA_HU
MAN 
AFMID arylformamidase Nucleus enzyme 
ALBU_HU
MAN 
ALB albumin Extracellul
ar Space 
transporter 
AMZ1_H
UMAN 
AMZ1 archaelysin family metallopeptidase 1 Other peptidase 
ANK2_HU
MAN 
ANK2 ankyrin 2, neuronal Plasma 
Membran
e 
other 
ANK3_HU
MAN 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) Plasma 
Membran
e 
other 
ANR12_H
UMAN 
ANKRD
12 
ankyrin repeat domain 12 Nucleus other 
ANR23_H
UMAN 
ANKRD
23 
ankyrin repeat domain 23 Nucleus other 
ANKUB_H
UMAN 
ANKUB
1 
ankyrin repeat and ubiquitin domain containing 1 Other other 
ANXA1_H
UMAN 
ANXA1 annexin A1 Plasma 
Membran
e 
other 
APOA1_H
UMAN 
APOA1 apolipoprotein A-I Extracellul
ar Space 
transporter 
APOB_HU
MAN 
APOB apolipoprotein B Extracellul
ar Space 
transporter 
ARAP3_H
UMAN 
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 Cytoplasm other 
ASPM_H
UMAN 
ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) Nucleus other 
ASXL2_H
UMAN 
ASXL2 additional sex combs like 2 (Drosophila) Extracellul
ar Space 
other 
RENR_HU
MAN 
ATP6A
P2 
ATPase, H+ transporting, lysosomal accessory protein 2 Cytoplasm transporter 
VPP1_HU
MAN 
ATP6V
0A1 
ATPase, H+ transporting, lysosomal V0 subunit a1 Cytoplasm transporter 
B4GT7_H
UMAN 
B4GAL
T7 
xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 Cytoplasm enzyme 
BLM_HU
MAN 
BLM Bloom syndrome, RecQ helicase-like Nucleus enzyme 
BRPF1_H
UMAN 
BRPF1 bromodomain and PHD finger containing, 1 Nucleus transporter 
CS068_H
UMAN 
C19orf
68 
chromosome 19 open reading frame 68 Other other 
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C1QC_HU
MAN 
C1QC complement component 1, q subcomponent, C chain Extracellul
ar Space 
other 
CO3_HU
MAN 
C3 complement component 3 Extracellul
ar Space 
peptidase 
CO4A_HU
MAN 
C4A/C4
B 
complement component 4B (Chido blood group) Extracellul
ar Space 
other 
C4BPA_H
UMAN 
C4BPA complement component 4 binding protein, alpha Extracellul
ar Space 
other 
CF062_H
UMAN 
C6orf6
2 
chromosome 6 open reading frame 62 Other other 
CAH3_HU
MAN 
CA3 carbonic anhydrase III, muscle specific Cytoplasm enzyme 
CATIN_H
UMAN 
CACTIN cactin, spliceosome C complex subunit Nucleus other 
CACO1_H
UMAN 
CALCO
CO1 
calcium binding and coiled-coil domain 1 Nucleus transcription 
regulator 
CC175_H
UMAN 
CCDC1
75 
coiled-coil domain containing 175 Other other 
CCD30_H
UMAN 
CCDC3
0 
coiled-coil domain containing 30 Other other 
CENPH_H
UMAN 
CENPH centromere protein H Nucleus other 
CFAH_HU
MAN 
CFH complement factor H Extracellul
ar Space 
other 
CHSS3_H
UMAN 
CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CMBL_HU
MAN 
CMBL carboxymethylenebutenolidase homolog (Pseudomonas) Other enzyme 
CO1A1_H
UMAN 
COL1A
1 
collagen, type I, alpha 1 Extracellul
ar Space 
other 
CO1A2_H
UMAN 
COL1A
2 
collagen, type I, alpha 2 Extracellul
ar Space 
other 
CROCC_H
UMAN 
CROCC ciliary rootlet coiled-coil, rootletin Plasma 
Membran
e 
other 
DIAC_HU
MAN 
CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CTRL_HU
MAN 
CTRL chymotrypsin-like Extracellul
ar Space 
peptidase 
CP1A2_H
UMAN 
CYP1A
2 
cytochrome P450, family 1, subfamily A, polypeptide 2 Cytoplasm enzyme 
DCD_HU
MAN 
DCD dermcidin Extracellul
ar Space 
other 
DCX_HU
MAN 
DCX doublecortin Cytoplasm other 
DHX57_H
UMAN 
DHX57 DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 Extracellul
ar Space 
other 
DYH2_HU
MAN 
DNAH2 dynein, axonemal, heavy chain 2 Other other 
DSCAM_H
UMAN 
DSCAM Down syndrome cell adhesion molecule Plasma 
Membran
e 
other 
DYHC2_H
UMAN 
DYNC2
H1 
dynein, cytoplasmic 2, heavy chain 1 Cytoplasm other 
COE2_HU
MAN 
EBF2 early B-cell factor 2 Nucleus other 
E2AK3_H
UMAN 
EIF2AK
3 
eukaryotic translation initiation factor 2-alpha kinase 3 Cytoplasm kinase 
ELF2_HU
MAN 
ELF2 E74-like factor 2 (ets domain transcription factor) Nucleus transcription 
regulator 
PERE_HU
MAN 
EPX eosinophil peroxidase Cytoplasm enzyme 
FABP5_H
UMAN 
FABP5 fatty acid binding protein 5 (psoriasis-associated) Cytoplasm transporter 
F196B_H
UMAN 
FAM19
6B 
family with sequence similarity 196, member B Other other 
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FIBA_HU
MAN 
FGA fibrinogen alpha chain Extracellul
ar Space 
other 
FIBB_HU
MAN 
FGB fibrinogen beta chain Extracellul
ar Space 
other 
FR1OP_H
UMAN 
FGFR1
OP 
FGFR1 oncogene partner Cytoplasm kinase 
FIBG_HU
MAN 
FGG fibrinogen gamma chain Extracellul
ar Space 
other 
FINC_HU
MAN 
FN1 fibronectin 1 Extracellul
ar Space 
enzyme 
GSH0_HU
MAN 
GCLM glutamate-cysteine ligase, modifier subunit Cytoplasm enzyme 
TF3C4_H
UMAN 
GTF3C
4 
general transcription factor IIIC, polypeptide 4, 90kDa Nucleus transcription 
regulator 
G6PE_HU
MAN 
H6PD hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) Cytoplasm enzyme 
HBB_HU
MAN 
HBB hemoglobin, beta Cytoplasm transporter 
HBG1_HU
MAN 
HBG1 hemoglobin, gamma A Cytoplasm other 
HILS1_HU
MAN 
HILS1 histone linker H1 domain, spermatid-specific 1, pseudogene Nucleus other 
H12_HU
MAN 
HIST1H
1C 
histone cluster 1, H1c Nucleus other 
H2A1A_H
UMAN 
HIST1H
2AA 
histone cluster 1, H2aa Nucleus other 
H2B1A_H
UMAN 
HIST1H
2BA 
histone cluster 1, H2ba Nucleus other 
BPL1_HU
MAN 
HLCS holocarboxylase synthetase (biotin-(proprionyl-CoA-carboxylase (ATP-hydrolysing)) 
ligase) 
Cytoplasm enzyme 
HMCN2_
HUMAN 
HMCN
2 
hemicentin 2 Extracellul
ar Space 
other 
GILT_HU
MAN 
IFI30 interferon, gamma-inducible protein 30 Cytoplasm enzyme 
IGHG1_H
UMAN 
IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Extracellul
ar Space 
other 
IGHM_HU
MAN 
IGHM immunoglobulin heavy constant mu Plasma 
Membran
e 
transmembrane 
receptor 
IGJ_HUM
AN 
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu 
polypeptides 
Extracellul
ar Space 
other 
IGKC_HU
MAN 
IGKC immunoglobulin kappa constant Extracellul
ar Space 
other 
KV401_H
UMAN 
IGKV4-
1 
immunoglobulin kappa variable 4-1 Extracellul
ar Space 
other 
LAC2_HU
MAN 
IGLC2 immunoglobulin lambda constant 2 (Kern-Oz- marker) Extracellul
ar Space 
other 
INCE_HU
MAN 
INCENP inner centromere protein antigens 135/155kDa Nucleus other 
KDM5A_
HUMAN 
KDM5A lysine (K)-specific demethylase 5A Nucleus transcription 
regulator 
TALD3_H
UMAN 
KIAA05
86 
KIAA0586 Cytoplasm other 
KIRR1_HU
MAN 
KIRREL kin of IRRE like (Drosophila) Plasma 
Membran
e 
other 
KLC2_HU
MAN 
KLC2 kinesin light chain 2 Cytoplasm other 
KLF1_HU
MAN 
KLF1 Kruppel-like factor 1 (erythroid) Nucleus transcription 
regulator 
K1C10_H
UMAN 
KRT10 keratin 10 Cytoplasm other 
K1C18_H
UMAN 
KRT18 keratin 18 Cytoplasm other 
K1C9_HU
MAN 
KRT9 keratin 9 Cytoplasm other 
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LDB1_HU
MAN 
LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
LHPL3_H
UMAN 
LHFPL3 lipoma HMGIC fusion partner-like 3 Other other 
LMNA_H
UMAN 
LMNA lamin A/C Nucleus other 
MA2A2_H
UMAN 
MAN2
A2 
mannosidase, alpha, class 2A, member 2 Cytoplasm enzyme 
MAP4_H
UMAN 
MAP4 microtubule-associated protein 4 Cytoplasm other 
MCLN2_H
UMAN 
MCOL
N2 
mucolipin 2 Plasma 
Membran
e 
ion channel 
MRE11_H
UMAN 
MRE11
A 
MRE11 meiotic recombination 11 homolog A (S. cerevisiae) Nucleus enzyme 
COX2_HU
MAN 
MT-
CO2 
cytochrome c oxidase subunit II Cytoplasm enzyme 
MYRIP_H
UMAN 
MYRIP myosin VIIA and Rab interacting protein Cytoplasm other 
ULA1_HU
MAN 
NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NOTC3_H
UMAN 
NOTCH
3 
notch 3 Plasma 
Membran
e 
transcription 
regulator 
NRX3A_H
UMAN 
NRXN3 neurexin 3 Other transporter 
NSN5C_H
UMAN 
NSUN5
P2 
NOP2/Sun domain family, member 5 pseudogene 2 Other other 
PALB2_H
UMAN 
PALB2 partner and localizer of BRCA2 Nucleus other 
MYOME_
HUMAN 
PDE4DI
P 
phosphodiesterase 4D interacting protein Cytoplasm enzyme 
PDP2_HU
MAN 
PDP2 pyruvate dehyrogenase phosphatase catalytic subunit 2 Cytoplasm phosphatase 
PDYN_HU
MAN 
PDYN prodynorphin Extracellul
ar Space 
transporter 
PI51B_HU
MAN 
PIP5K1
B 
phosphatidylinositol-4-phosphate 5-kinase, type I, beta Cytoplasm kinase 
PKD2_HU
MAN 
PKD2 polycystic kidney disease 2 (autosomal dominant) Plasma 
Membran
e 
ion channel 
PMYT1_H
UMAN 
PKMYT
1 
protein kinase, membrane associated tyrosine/threonine 1 Cytoplasm kinase 
PLCL2_HU
MAN 
PLCL2 phospholipase C-like 2 Cytoplasm enzyme 
PNKD_HU
MAN 
PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
RPC2_HU
MAN 
POLR3
B 
polymerase (RNA) III (DNA directed) polypeptide B Nucleus enzyme 
PPIG_HU
MAN 
PPIG peptidylprolyl isomerase G (cyclophilin G) Nucleus enzyme 
PRDX2_H
UMAN 
PRDX2 peroxiredoxin 2 Cytoplasm enzyme 
PRDX6_H
UMAN 
PRDX6 peroxiredoxin 6 Cytoplasm enzyme 
PTGDS_H
UMAN 
PTGDS prostaglandin D2 synthase 21kDa (brain) Cytoplasm enzyme 
RAB10_H
UMAN 
RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
RAB6A_H
UMAN 
RAB6A RAB6A, member RAS oncogene family Cytoplasm enzyme 
RBM23_H
UMAN 
RBM23 RNA binding motif protein 23 Nucleus other 
REG1A_H
UMAN 
REG1A regenerating islet-derived 1 alpha Extracellul
ar Space 
growth factor 
RS16_HU RPS16 ribosomal protein S16 Cytoplasm other 
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MAN 
RS27A_H
UMAN 
RPS27
A 
ribosomal protein S27a Cytoplasm other 
RL1D1_H
UMAN 
RSL1D1 ribosomal L1 domain containing 1 Nucleus other 
RSPO1_H
UMAN 
RSPO1 R-spondin 1 Plasma 
Membran
e 
other 
RXRB_HU
MAN 
RXRB retinoid X receptor, beta Nucleus ligand-dependent 
nuclear receptor 
DHSA_HU
MAN 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) Cytoplasm enzyme 
SEM5B_H
UMAN 
SEMA5
B 
sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B 
Plasma 
Membran
e 
other 
SPD2A_H
UMAN 
SH3PX
D2A 
SH3 and PX domains 2A Cytoplasm other 
SHAN1_H
UMAN 
SHANK
1 
SH3 and multiple ankyrin repeat domains 1 Cytoplasm other 
CTL1_HU
MAN 
SLC44A
1 
solute carrier family 44 (choline transporter), member 1 Plasma 
Membran
e 
transporter 
SMC5_HU
MAN 
SMC5 structural maintenance of chromosomes 5 Nucleus other 
SPAG7_H
UMAN 
SPAG7 sperm associated antigen 7 Nucleus other 
SPA2L_H
UMAN 
SPATA
2L 
spermatogenesis associated 2-like Other other 
SRG2C_H
UMAN 
SRGAP
2C 
SLIT-ROBO Rho GTPase activating protein 2C Other other 
SIA7B_HU
MAN 
ST6GAL
NAC2 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 2 
Cytoplasm enzyme 
SYNE1_H
UMAN 
SYNE1 spectrin repeat containing, nuclear envelope 1 Nucleus other 
TBX20_H
UMAN 
TBX20 T-box 20 Nucleus transcription 
regulator 
TET1_HU
MAN 
TET1 tet methylcytosine dioxygenase 1 Nucleus other 
TLK2_HU
MAN 
TLK2 tousled-like kinase 2 Cytoplasm kinase 
T151A_H
UMAN 
TMEM
151A 
transmembrane protein 151A Other other 
TM232_H
UMAN 
TMEM
232 
transmembrane protein 232 Other other 
TMM95_
HUMAN 
TMEM
95 
transmembrane protein 95 Other other 
TPD54_H
UMAN 
TPD52L
2 
tumor protein D52-like 2 Cytoplasm other 
TPRN_HU
MAN 
TPRN taperin Extracellul
ar Space 
other 
TARA_HU
MAN 
TRIOBP TRIO and F-actin binding protein Nucleus other 
TTBK2_H
UMAN 
TTBK2 tau tubulin kinase 2 Other kinase 
TITIN_HU
MAN 
TTN titin Other kinase 
UBR2_HU
MAN 
UBR2 ubiquitin protein ligase E3 component n-recognin 2 Nucleus enzyme 
UN13A_H
UMAN 
UNC13
A 
unc-13 homolog A (C. elegans) Plasma 
Membran
e 
other 
UNC79_H
UMAN 
UNC79 unc-79 homolog (C. elegans) Extracellul
ar Space 
other 
MELT_HU
MAN 
VEPH1 ventricular zone expressed PH domain-containing 1 Nucleus other 
VIME_HU VIM vimentin Cytoplasm other 
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MAN 
WDR1_H
UMAN 
WDR1 WD repeat domain 1 Extracellul
ar Space 
other 
WDR43_H
UMAN 
WDR43 WD repeat domain 43 Nucleus other 
1433T_H
UMAN 
YWHA
Q 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta 
polypeptide 
Cytoplasm other 
ZN345_H
UMAN 
ZNF34
5 
zinc finger protein 345 Nucleus transcription 
regulator 
ZN516_H
UMAN 
ZNF51
6 
zinc finger protein 516 Nucleus other 
ZN671_H
UMAN 
ZNF67
1 
zinc finger protein 671 Nucleus other 
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7 week (n=10). 
 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
ATS16_HUMAN ADAMTS16 ADAM metallopeptidase with thrombospondin 
type 1 motif, 16 
Extracellular 
Space 
other 
DSRAD_HUMAN ADAR adenosine deaminase, RNA-specific Nucleus enzyme 
ADCY7_HUMAN ADCY7 adenylate cyclase 7 Plasma 
Membrane 
enzyme 
PLCA_HUMAN AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 Cytoplasm enzyme 
AICDA_HUMAN AICDA activation-induced cytidine deaminase Cytoplasm enzyme 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
AMZ1_HUMAN AMZ1 archaelysin family metallopeptidase 1 Other peptidase 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
ANR26_HUMAN ANKRD26 ankyrin repeat domain 26 Nucleus transcription 
regulator 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
APOB_HUMAN APOB apolipoprotein B Extracellular 
Space 
transporter 
ASPH2_HUMAN ASPHD2 aspartate beta-hydroxylase domain containing 2 Other enzyme 
BEND4_HUMAN BEND4 BEN domain containing 4 Other other 
BLMH_HUMAN BLMH bleomycin hydrolase Cytoplasm peptidase 
C1QC_HUMAN C1QC complement component 1, q subcomponent, C 
chain 
Extracellular 
Space 
other 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
CO4A_HUMAN C4A/C4B complement component 4B (Chido blood group) Extracellular 
Space 
other 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
C8AP2_HUMAN CASP8AP2 caspase 8 associated protein 2 Nucleus transcription 
regulator 
CC154_HUMAN CCDC154 coiled-coil domain containing 154 Other other 
CCD70_HUMAN CCDC70 coiled-coil domain containing 70 Plasma 
Membrane 
other 
CCD80_HUMAN CCDC80 coiled-coil domain containing 80 Nucleus other 
CCHCR_HUMAN CCHCR1 coiled-coil alpha-helical rod protein 1 Cytoplasm other 
CFAH_HUMAN CFH complement factor H Extracellular 
Space 
other 
CHSTB_HUMAN CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 Cytoplasm enzyme 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CILP1_HUMAN CILP cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 
Extracellular 
Space 
phosphatase 
CLUS_HUMAN CLU clusterin Cytoplasm other 
CMBL_HUMAN CMBL carboxymethylenebutenolidase homolog 
(Pseudomonas) 
Other enzyme 
CNO6L_HUMAN CNOT6L CCR4-NOT transcription complex, subunit 6-like Cytoplasm enzyme 
CPXM2_HUMAN CPXM2 carboxypeptidase X (M14 family), member 2 Extracellular 
Space 
peptidase 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CTRL_HUMAN CTRL chymotrypsin-like Extracellular 
Space 
peptidase 
C19L2_HUMAN CWF19L2 CWF19-like 2, cell cycle control (S. pombe) Other other 
DAPL1_HUMAN DAPL1 death associated protein-like 1 Other other 
DCD_HUMAN DCD dermcidin Extracellular 
Space 
other 
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DMXL1_HUMAN DMXL1 Dmx-like 1 Extracellular 
Space 
other 
DYH17_HUMAN DNAH17 dynein, axonemal, heavy chain 17 Cytoplasm other 
EBP_HUMAN EBP emopamil binding protein (sterol isomerase) Cytoplasm enzyme 
ENPP5_HUMAN ENPP5 ectonucleotide 
pyrophosphatase/phosphodiesterase 5 (putative) 
Extracellular 
Space 
enzyme 
EPHAA_HUMAN EPHA10 EPH receptor A10 Plasma 
Membrane 
transmembrane 
receptor 
PERE_HUMAN EPX eosinophil peroxidase Cytoplasm enzyme 
EXOS1_HUMAN EXOSC1 exosome component 1 Nucleus enzyme 
FBF1_HUMAN FBF1 Fas (TNFRSF6) binding factor 1 Nucleus other 
FIBA_HUMAN FGA fibrinogen alpha chain Extracellular 
Space 
other 
FIBB_HUMAN FGB fibrinogen beta chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FGFR2_HUMAN FGFR2 fibroblast growth factor receptor 2 Plasma 
Membrane 
kinase 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
GLI2_HUMAN GLI2 GLI family zinc finger 2 Nucleus transcription 
regulator 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, soluble Cytoplasm enzyme 
GP126_HUMAN GPR126 G protein-coupled receptor 126 Plasma 
Membrane 
G-protein coupled 
receptor 
HERC1_HUMAN HERC1 HECT and RLD domain containing E3 ubiquitin 
protein ligase family member 1 
Cytoplasm other 
BPL1_HUMAN HLCS holocarboxylase synthetase (biotin-(proprionyl-
CoA-carboxylase (ATP-hydrolysing)) ligase) 
Cytoplasm enzyme 
HPTR_HUMAN HPR haptoglobin-related protein Extracellular 
Space 
peptidase 
HS3S6_HUMAN HS3ST6 heparan sulfate (glucosamine) 3-O-
sulfotransferase 6 
Cytoplasm enzyme 
5HT2A_HUMAN HTR2A 5-hydroxytryptamine (serotonin) receptor 2A, G 
protein-coupled 
Plasma 
Membrane 
G-protein coupled 
receptor 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 (G1m 
marker) 
Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
IGJ_HUMAN IGJ immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
Extracellular 
Space 
other 
IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
LAC1_HUMAN IGLC1 immunoglobulin lambda constant 1 (Mcg marker) Cytoplasm other 
IQCF6_HUMAN IQCF6 IQ motif containing F6 Other other 
JARD2_HUMAN JARID2 jumonji, AT rich interactive domain 2 Nucleus transcription 
regulator 
KTNB1_HUMAN KATNB1 katanin p80 (WD repeat containing) subunit B 1 Cytoplasm enzyme 
KCND2_HUMAN KCND2 potassium voltage-gated channel, Shal-related 
subfamily, member 2 
Plasma 
Membrane 
ion channel 
KI13A_HUMAN KIF13A kinesin family member 13A Cytoplasm transporter 
KIRR1_HUMAN KIRREL kin of IRRE like (Drosophila) Plasma 
Membrane 
other 
KLC2_HUMAN KLC2 kinesin light chain 2 Cytoplasm other 
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other 
K1C10_HUMAN KRT10 keratin 10 Cytoplasm other 
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K1C9_HUMAN KRT9 keratin 9 Cytoplasm other 
LDB1_HUMAN LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
LIPC_HUMAN LIPC lipase, hepatic Extracellular 
Space 
enzyme 
LZTR1_HUMAN LZTR1 leucine-zipper-like transcription regulator 1 Cytoplasm transcription 
regulator 
MDN1_HUMAN MDN1 MDN1, midasin homolog (yeast) Nucleus other 
MKL1_HUMAN MKL1 megakaryoblastic leukemia (translocation) 1 Nucleus transcription 
regulator 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NHS_HUMAN NHS Nance-Horan syndrome (congenital cataracts and 
dental anomalies) 
Nucleus other 
NRX3A_HUMAN NRXN3 neurexin 3 Other transporter 
NSD1_HUMAN NSD1 nuclear receptor binding SET domain protein 1 Nucleus transcription 
regulator 
OR8K1_HUMAN OR8K1 olfactory receptor, family 8, subfamily K, member 
1 
Plasma 
Membrane 
G-protein coupled 
receptor 
PCDBC_HUMAN PCDHB12 protocadherin beta 12 Plasma 
Membrane 
other 
PEAK1_HUMAN PEAK1 NKF3 kinase family member Plasma 
Membrane 
kinase 
PFD6_HUMAN PFDN6 prefoldin subunit 6 Cytoplasm other 
PGP_HUMAN PGP phosphoglycolate phosphatase Other enzyme 
PIGS_HUMAN PIGS phosphatidylinositol glycan anchor biosynthesis, 
class S 
Cytoplasm enzyme 
PNKD_HUMAN PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
PP1R7_HUMAN PPP1R7 protein phosphatase 1, regulatory subunit 7 Nucleus phosphatase 
PREB_HUMAN PREB prolactin regulatory element binding Nucleus transcription 
regulator 
RAB10_HUMAN RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
RGPA2_HUMAN RALGAPA2 Ral GTPase activating protein, alpha subunit 2 
(catalytic) 
Cytoplasm other 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA binding 
domain 
Other other 
RN213_HUMAN RNF213 ring finger protein 213 Other enzyme 
FTM_HUMAN RPGRIP1L RPGRIP1-like Cytoplasm other 
RL37_HUMAN RPL37 ribosomal protein L37 Cytoplasm other 
RL1D1_HUMAN RSL1D1 ribosomal L1 domain containing 1 Nucleus other 
RSPO1_HUMAN RSPO1 R-spondin 1 Plasma 
Membrane 
other 
RTN4_HUMAN RTN4 reticulon 4 Cytoplasm other 
RYR2_HUMAN RYR2 ryanodine receptor 2 (cardiac) Plasma 
Membrane 
ion channel 
UTER_HUMAN SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Extracellular 
Space 
cytokine 
SHAN1_HUMAN SHANK1 SH3 and multiple ankyrin repeat domains 1 Cytoplasm other 
S27A2_HUMAN SLC27A2 solute carrier family 27 (fatty acid transporter), 
member 2 
Cytoplasm transporter 
CTL1_HUMAN SLC44A1 solute carrier family 44 (choline transporter), 
member 1 
Plasma 
Membrane 
transporter 
SP100_HUMAN SP100 SP100 nuclear antigen Nucleus transcription 
regulator 
SPO11_HUMAN SPO11 SPO11 meiotic protein covalently bound to DSB Nucleus enzyme 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other 
SP20H_HUMAN SUPT20H suppressor of Ty 20 homolog (S. cerevisiae) Nucleus other 
SPT6H_HUMAN SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) Nucleus transcription 
regulator 
SVEP1_HUMAN SVEP1 sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1 
Cytoplasm other 
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BROMI_HUMAN TBC1D32 TBC1 domain family, member 32 Other other 
TET1_HUMAN TET1 tet methylcytosine dioxygenase 1 Nucleus other 
TLK2_HUMAN TLK2 tousled-like kinase 2 Cytoplasm kinase 
TRA2B_HUMAN TRA2B transformer 2 beta homolog (Drosophila) Nucleus other 
TRML4_HUMAN TREML4 triggering receptor expressed on myeloid cells-like 
4 
Other other 
TARA_HUMAN TRIOBP TRIO and F-actin binding protein Nucleus other 
TITIN_HUMAN TTN titin Other kinase 
UBR2_HUMAN UBR2 ubiquitin protein ligase E3 component n-recognin 
2 
Nucleus enzyme 
UGDH_HUMAN UGDH UDP-glucose 6-dehydrogenase Nucleus enzyme 
VP13C_HUMAN VPS13C vacuolar protein sorting 13 homolog C (S. 
cerevisiae) 
Other other 
WAC_HUMAN WAC WW domain containing adaptor with coiled-coil Nucleus other 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
WDR35_HUMAN WDR35 WD repeat domain 35 Cytoplasm other 
ZFHX4_HUMAN ZFHX4 zinc finger homeobox 4 Extracellular 
Space 
other 
ZMYM3_HUMAN ZMYM3 zinc finger, MYM-type 3 Nucleus other 
ZN132_HUMAN ZNF132 zinc finger protein 132 Nucleus transcription 
regulator 
ZN345_HUMAN ZNF345 zinc finger protein 345 Nucleus transcription 
regulator 
ZN532_HUMAN ZNF532 zinc finger protein 532 Other other 
ZN624_HUMAN ZNF624 zinc finger protein 624 Nucleus other 
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8 week (n=10). 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
ACTN3_HUMAN ACTN3 actinin, alpha 3 Other other 
ADA12_HUMAN ADAM12 ADAM metallopeptidase domain 12 Plasma 
Membrane 
peptidase 
AICDA_HUMAN AICDA activation-induced cytidine deaminase Cytoplasm enzyme 
AKAP9_HUMAN AKAP9 A kinase (PRKA) anchor protein 9 Cytoplasm other 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
AMZ1_HUMAN AMZ1 archaelysin family metallopeptidase 1 Other peptidase 
ANK2_HUMAN ANK2 ankyrin 2, neuronal Plasma 
Membrane 
other 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
AT2A3_HUMAN ATP2A3 ATPase, Ca++ transporting, ubiquitous Cytoplasm transporter 
BAI2_HUMAN BAI2 brain-specific angiogenesis inhibitor 2 Plasma 
Membrane 
G-protein 
coupled 
receptor 
BLMH_HUMAN BLMH bleomycin hydrolase Cytoplasm peptidase 
BMP3_HUMAN BMP3 bone morphogenetic protein 3 Extracellular 
Space 
growth factor 
CP013_HUMAN C16orf13 chromosome 16 open reading frame 13 Other other 
CA174_HUMAN C1orf174 chromosome 1 open reading frame 174 Other other 
C1QC_HUMAN C1QC complement component 1, q subcomponent, C chain Extracellular 
Space 
other 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
CI078_HUMAN C9orf78 chromosome 9 open reading frame 78 Other other 
CAND1_HUMAN CAND1 cullin-associated and neddylation-dissociated 1 Cytoplasm transcription 
regulator 
CDRT1_HUMAN CDRT1 CMT1A duplicated region transcript 1 Other other 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CLC4M_HUMAN CLEC4M C-type lectin domain family 4, member M Plasma 
Membrane 
other 
CMBL_HUMAN CMBL carboxymethylenebutenolidase homolog (Pseudomonas) Other enzyme 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CTRL_HUMAN CTRL chymotrypsin-like Extracellular 
Space 
peptidase 
DCD_HUMAN DCD dermcidin Extracellular 
Space 
other 
DCR1B_HUMAN DCLRE1B DNA cross-link repair 1B Nucleus enzyme 
DCSTP_HUMAN DCSTAMP dendrocyte expressed seven transmembrane protein Plasma 
Membrane 
other 
DDX51_HUMAN DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 Other enzyme 
DDX6L_HUMAN DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like Other other 
DIP2B_HUMAN DIP2B DIP2 disco-interacting protein 2 homolog B (Drosophila) Other other 
DYH11_HUMAN DNAH11 dynein, axonemal, heavy chain 11 Cytoplasm enzyme 
DYH17_HUMAN DNAH17 dynein, axonemal, heavy chain 17 Cytoplasm other 
DTNA_HUMAN DTNA dystrobrevin, alpha Plasma 
Membrane 
other 
EXOC8_HUMAN EXOC8 exocyst complex component 8 Plasma 
Membrane 
other 
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NIBL2_HUMAN FAM129C family with sequence similarity 129, member C Other other 
FIBA_HUMAN FGA fibrinogen alpha chain Extracellular 
Space 
other 
FIBB_HUMAN FGB fibrinogen beta chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FLNB_HUMAN FLNB filamin B, beta Cytoplasm other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
FSIP2_HUMAN FSIP2 fibrous sheath interacting protein 2 Cytoplasm other 
GAK_HUMAN GAK cyclin G associated kinase Nucleus kinase 
GDF6_HUMAN GDF6 growth differentiation factor 6 Extracellular 
Space 
growth factor 
GIMA8_HUMAN GIMAP8 GTPase, IMAP family member 8 Other other 
GMEB1_HUMAN GMEB1 glucocorticoid modulatory element 
binding protein 1 
Nucleus transcription 
regulator 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, 
soluble 
Cytoplasm enzyme 
GSHB_HUMAN GSS glutathione synthetase Cytoplasm enzyme 
HAS2_HUMAN HAS2 hyaluronan synthase 2 Plasma 
Membrane 
enzyme 
HBG1_HUMAN HBG1 hemoglobin, gamma A Cytoplasm other 
HERC1_HUMAN HERC1 HECT and RLD domain containing E3 
ubiquitin protein ligase family member 1 
Cytoplasm other 
HILS1_HUMAN HILS1 histone linker H1 domain, spermatid-
specific 1, pseudogene 
Nucleus other 
HIP1_HUMAN HIP1 huntingtin interacting protein 1 Cytoplasm other 
BPL1_HUMAN HLCS holocarboxylase synthetase (biotin-
(proprionyl-CoA-carboxylase (ATP-
hydrolysing)) ligase) 
Cytoplasm enzyme 
HS3S6_HUMAN HS3ST6 heparan sulfate (glucosamine) 3-O-
sulfotransferase 6 
Cytoplasm enzyme 
5HT2A_HUMAN HTR2A 5-hydroxytryptamine (serotonin) receptor 
2A, G protein-coupled 
Plasma 
Membrane 
G-protein 
coupled 
receptor 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 
(G1m marker) 
Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
LAC1_HUMAN IGLC1 immunoglobulin lambda constant 1 (Mcg 
marker) 
Cytoplasm other 
IHH_HUMAN IHH indian hedgehog Extracellular 
Space 
enzyme 
RED_HUMAN IK IK cytokine, down-regulator of HLA II Extracellular 
Space 
cytokine 
IL1AP_HUMAN IL1RAP interleukin 1 receptor accessory protein Plasma 
Membrane 
transmembrane 
receptor 
IRPL2_HUMAN IL1RAPL2 interleukin 1 receptor accessory protein-
like 2 
Plasma 
Membrane 
transmembrane 
receptor 
KCNQ5_HUMAN KCNQ5 potassium voltage-gated channel, KQT-
like subfamily, member 5 
Plasma 
Membrane 
ion channel 
KIF19_HUMAN KIF19 kinesin family member 19 Extracellular 
Space 
enzyme 
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other 
K1C10_HUMAN KRT10 keratin 10 Cytoplasm other 
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K1C14_HUMAN KRT14 keratin 14 Cytoplasm other 
K1C9_HUMAN KRT9 keratin 9 Cytoplasm other 
LDB1_HUMAN LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
YP023_HUMAN LOC100128265 uncharacterized LOC100128265 Other other 
LRC32_HUMAN LRRC32 leucine rich repeat containing 32 Plasma 
Membrane 
other 
MBD5_HUMAN MBD5 methyl-CpG binding domain protein 5 Other other 
MYBA_HUMAN MYBL1 v-myb avian myeloblastosis viral 
oncogene homolog-like 1 
Nucleus transcription 
regulator 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NUCL_HUMAN NCL nucleolin Nucleus other 
NDUF4_HUMAN NDUFAF4 NADH dehydrogenase (ubiquinone) 
complex I, assembly factor 4 
Cytoplasm other 
NRX3A_HUMAN NRXN3 neurexin 3 Other transporter 
ODFP2_HUMAN ODF2 outer dense fiber of sperm tails 2 Cytoplasm other 
NOE2_HUMAN OLFM2 olfactomedin 2 Cytoplasm other 
PARP4_HUMAN PARP4 poly (ADP-ribose) polymerase family, 
member 4 
Other enzyme 
PCDBC_HUMAN PCDHB12 protocadherin beta 12 Plasma 
Membrane 
other 
PLCD3_HUMAN PLCD3 phospholipase C, delta 3 Cytoplasm enzyme 
PNKD_HUMAN PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
PNKP_HUMAN PNKP polynucleotide kinase 3'-phosphatase Nucleus kinase 
PPT2_HUMAN PPT2 palmitoyl-protein thioesterase 2 Cytoplasm enzyme 
PRC2A_HUMAN PRRC2A proline-rich coiled-coil 2A Cytoplasm other 
PTN13_HUMAN PTPN13 protein tyrosine phosphatase, non-
receptor type 13 (APO-1/CD95 (Fas)-
associated phosphatase) 
Cytoplasm phosphatase 
RAB10_HUMAN RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
RBCC1_HUMAN RB1CC1 RB1-inducible coiled-coil 1 Nucleus other 
REG1A_HUMAN REG1A regenerating islet-derived 1 alpha Extracellular 
Space 
growth factor 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA 
binding domain 
Other other 
RN180_HUMAN RNF180 ring finger protein 180 Cytoplasm enzyme 
RL1D1_HUMAN RSL1D1 ribosomal L1 domain containing 1 Nucleus other 
SARM1_HUMAN SARM1 sterile alpha and TIR motif containing 1 Plasma 
Membrane 
transmembrane 
receptor 
SASH1_HUMAN SASH1 SAM and SH3 domain containing 1 Extracellular 
Space 
other 
SPB9_HUMAN SERPINB9 serpin peptidase inhibitor, clade B 
(ovalbumin), member 9 
Cytoplasm other 
SHAN3_HUMAN SHANK3 SH3 and multiple ankyrin repeat domains 
3 
Plasma 
Membrane 
other 
S27A2_HUMAN SLC27A2 solute carrier family 27 (fatty acid 
transporter), member 2 
Cytoplasm transporter 
SPAG7_HUMAN SPAG7 sperm associated antigen 7 Nucleus other 
SPA2L_HUMAN SPATA2L spermatogenesis associated 2-like Other other 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 
2 
Cytoplasm other 
SRG2C_HUMAN SRGAP2C SLIT-ROBO Rho GTPase activating protein 
2C 
Other other 
SIA7B_HUMAN ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 2 
Cytoplasm enzyme 
SVEP1_HUMAN SVEP1 sushi, von Willebrand factor type A, EGF 
and pentraxin domain containing 1 
Cytoplasm other 
TBX20_HUMAN TBX20 T-box 20 Nucleus transcription 
regulator 
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TFP11_HUMAN TFIP11 tuftelin interacting protein 11 Extracellular 
Space 
other 
TMM95_HUMAN TMEM95 transmembrane protein 95 Other other 
TARA_HUMAN TRIOBP TRIO and F-actin binding protein Nucleus other 
TTBK2_HUMAN TTBK2 tau tubulin kinase 2 Other kinase 
TITIN_HUMAN TTN titin Other kinase 
TRXR3_HUMAN TXNRD3 thioredoxin reductase 3 Cytoplasm enzyme 
UBR2_HUMAN UBR2 ubiquitin protein ligase E3 component n-
recognin 2 
Nucleus enzyme 
VASH2_HUMAN VASH2 vasohibin 2 Cytoplasm other 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
YIPF1_HUMAN YIPF1 Yip1 domain family, member 1 Cytoplasm other 
TUT4_HUMAN ZCCHC11 zinc finger, CCHC domain containing 11 Nucleus enzyme 
ZF64B_HUMAN ZFP64 ZFP64 zinc finger protein Nucleus other 
ZNF14_HUMAN ZNF14 zinc finger protein 14 Nucleus transcription 
regulator 
ZN285_HUMAN ZNF285 zinc finger protein 285 Nucleus other 
ZN624_HUMAN ZNF624 zinc finger protein 624 Nucleus other 
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9 week (n=10). 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
A2ML1_HUMAN A2ML1 alpha-2-macroglobulin-like 1 Cytoplasm other 
ADAL_HUMAN ADAL adenosine deaminase-like Cytoplasm enzyme 
KFA_HUMAN AFMID arylformamidase Nucleus enzyme 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
AMZ1_HUMAN AMZ1 archaelysin family metallopeptidase 1 Other peptidase 
ANKAR_HUMAN ANKAR ankyrin and armadillo repeat containing Nucleus transcription 
regulator 
ANKL1_HUMAN ANKLE1 ankyrin repeat and LEM domain containing 1 Other other 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
RHG08_HUMAN ARHGAP8/PRR5-
ARHGAP8 
Rho GTPase activating protein 8 Cytoplasm other 
ARHGB_HUMAN ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 Cytoplasm other 
B4GT7_HUMAN B4GALT7 xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 Cytoplasm enzyme 
CA228_HUMAN C1orf228 chromosome 1 open reading frame 228 Other other 
C1QC_HUMAN C1QC complement component 1, q subcomponent, C chain Extracellular 
Space 
other 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
CAND1_HUMAN CAND1 cullin-associated and neddylation-dissociated 1 Cytoplasm transcription 
regulator 
CAN1_HUMAN CAPN1 calpain 1, (mu/I) large subunit Cytoplasm peptidase 
CAN2_HUMAN CAPN2 calpain 2, (m/II) large subunit Cytoplasm peptidase 
CASC5_HUMAN CASC5 cancer susceptibility candidate 5 Nucleus other 
ACHG_HUMAN CHRNG cholinergic receptor, nicotinic, gamma (muscle) Plasma 
Membrane 
transmembrane 
receptor 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CLNK_HUMAN CLNK cytokine-dependent hematopoietic cell linker Cytoplasm other 
CMBL_HUMAN CMBL carboxymethylenebutenolidase homolog (Pseudomonas) Other enzyme 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CP51A_HUMAN CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 Cytoplasm enzyme 
DDX51_HUMAN DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 Other enzyme 
DUS3L_HUMAN DUS3L dihydrouridine synthase 3-like (S. cerevisiae) Other other 
EIF3C_HUMAN EIF3C/EIF3CL eukaryotic translation initiation factor 3, subunit C Cytoplasm translation 
regulator 
F208B_HUMAN FAM208B family with sequence similarity 208, member B Other other 
FA78B_HUMAN FAM78B family with sequence similarity 78, member B Other other 
FIBA_HUMAN FGA fibrinogen alpha chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FHAD1_HUMAN FHAD1 forkhead-associated (FHA) phosphopeptide binding domain 1 Other other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
G6PC2_HUMAN G6PC2 glucose-6-phosphatase, catalytic, 2 Cytoplasm phosphatase 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, soluble Cytoplasm enzyme 
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HERC1_HUMAN HERC1 HECT and RLD domain containing E3 ubiquitin protein ligase family 
member 1 
Cytoplasm other 
HIP1_HUMAN HIP1 huntingtin interacting protein 1 Cytoplasm other 
HJURP_HUMAN HJURP Holliday junction recognition protein Nucleus other 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
LAC1_HUMAN IGLC1 immunoglobulin lambda constant 1 (Mcg marker) Cytoplasm other 
IL1AP_HUMAN IL1RAP interleukin 1 receptor accessory protein Plasma 
Membrane 
transmembrane 
receptor 
K1161_HUMAN KIAA1161 KIAA1161 Nucleus other 
KIRR1_HUMAN KIRREL kin of IRRE like (Drosophila) Plasma 
Membrane 
other 
KLC2_HUMAN KLC2 kinesin light chain 2 Cytoplasm other 
LIPC_HUMAN LIPC lipase, hepatic Extracellular 
Space 
enzyme 
MANF_HUMAN MANF mesencephalic astrocyte-derived neurotrophic factor Extracellular 
Space 
other 
MAP4_HUMAN MAP4 microtubule-associated protein 4 Cytoplasm other 
RM32_HUMAN MRPL32 mitochondrial ribosomal protein L32 Cytoplasm translation 
regulator 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NEBU_HUMAN NEB nebulin Other other 
NEDD4_HUMAN NEDD4 neural precursor cell expressed, developmentally down-regulated 4, 
E3 ubiquitin protein ligase 
Cytoplasm enzyme 
NOA1_HUMAN NOA1 nitric oxide associated 1 Cytoplasm other 
NUD15_HUMAN NUDT15 nudix (nucleoside diphosphate linked moiety X)-type motif 15 Cytoplasm phosphatase 
OPN4_HUMAN OPN4 opsin 4 Plasma 
Membrane 
G-protein 
coupled 
receptor 
OR4K1_HUMAN OR4K1 olfactory receptor, family 4, subfamily K, member 1 Plasma 
Membrane 
G-protein 
coupled 
receptor 
PER3_HUMAN PER3 period circadian clock 3 Nucleus other 
P3C2A_HUMAN PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 
alpha 
Cytoplasm kinase 
DPOLQ_HUMAN POLQ polymerase (DNA directed), theta Nucleus enzyme 
PMGT1_HUMAN POMGNT1 protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 
1,2-) 
Cytoplasm enzyme 
PP12C_HUMAN PPP1R12C protein phosphatase 1, regulatory subunit 12C Cytoplasm phosphatase 
PSB3_HUMAN PSMB3 proteasome (prosome, macropain) subunit, beta type, 3 Cytoplasm peptidase 
PTPRM_HUMAN PTPRM protein tyrosine phosphatase, receptor type, M Plasma 
Membrane 
phosphatase 
RAB10_HUMAN RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
RB3GP_HUMAN RAB3GAP1 RAB3 GTPase activating protein subunit 1 (catalytic) Cytoplasm other 
RELN_HUMAN RELN reelin Extracellular 
Space 
peptidase 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA binding domain Other other 
RMND1_HUMAN RMND1 required for meiotic nuclear division 1 homolog (S. cerevisiae) Cytoplasm other 
SCUB3_HUMAN SCUBE3 signal peptide, CUB domain, EGF-like 3 Plasma 
Membrane 
other 
SHAN1_HUMAN SHANK1 SH3 and multiple ankyrin repeat domains 1 Cytoplasm other 
SPAG7_HUMAN SPAG7 sperm associated antigen 7 Nucleus other 
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SPA2L_HUMAN SPATA2L spermatogenesis associated 2-like Other other 
SPO11_HUMAN SPO11 SPO11 meiotic protein covalently bound to DSB Nucleus enzyme 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other 
SIA7B_HUMAN ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
Cytoplasm enzyme 
TBX20_HUMAN TBX20 T-box 20 Nucleus transcription 
regulator 
TDRD1_HUMAN TDRD1 tudor domain containing 1 Cytoplasm other 
TET1_HUMAN TET1 tet methylcytosine dioxygenase 1 Nucleus other 
TM131_HUMAN TMEM131 transmembrane protein 131 Extracellular 
Space 
other 
TRI65_HUMAN TRIM65 tripartite motif containing 65 Other other 
TRPC5_HUMAN TRPC5 transient receptor potential cation channel, subfamily C, member 5 Plasma 
Membrane 
ion channel 
GCP6_HUMAN TUBGCP6 tubulin, gamma complex associated protein 6 Cytoplasm other 
USP9X_HUMAN USP9X ubiquitin specific peptidase 9, X-linked Plasma 
Membrane 
peptidase 
VP13C_HUMAN VPS13C vacuolar protein sorting 13 homolog C (S. cerevisiae) Other other 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
WDR35_HUMAN WDR35 WD repeat domain 35 Cytoplasm other 
ZFHX4_HUMAN ZFHX4 zinc finger homeobox 4 Extracellular 
Space 
other 
Z286B_HUMAN ZNF286B zinc finger protein 286B Other other 
ZN345_HUMAN ZNF345 zinc finger protein 345 Nucleus transcription 
regulator 
ZN624_HUMAN ZNF624 zinc finger protein 624 Nucleus other 
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10 week (n=10). 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
GABT_HUMAN ABAT 4-aminobutyrate aminotransferase Cytoplasm enzyme 
ABCF1_HUMAN ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 Cytoplasm transporter 
ACTT1_HUMAN ACTRT1 actin-related protein T1 Cytoplasm other 
ADA12_HUMAN ADAM12 ADAM metallopeptidase domain 12 Plasma 
Membrane 
peptidase 
AICDA_HUMAN AICDA activation-induced cytidine deaminase Cytoplasm enzyme 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
ANK2_HUMAN ANK2 ankyrin 2, neuronal Plasma 
Membrane 
other 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
ANR31_HUMAN ANKRD31 ankyrin repeat domain 31 Extracellular 
Space 
other 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
APOL1_HUMAN APOL1 apolipoprotein L, 1 Extracellular 
Space 
transporter 
APOP1_HUMAN APOPT1 apoptogenic 1, mitochondrial Cytoplasm other 
DP13B_HUMAN APPL2 adaptor protein, phosphotyrosine interaction, PH domain and 
leucine zipper containing 2 
Cytoplasm other 
ATOH8_HUMAN ATOH8 atonal homolog 8 (Drosophila) Other other 
OSTCN_HUMAN BGLAP bone gamma-carboxyglutamate (gla) protein Extracellular 
Space 
other 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
CO4A_HUMAN C4A/C4B complement component 4B (Chido blood group) Extracellular 
Space 
other 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
CABIN_HUMAN CABIN1 calcineurin binding protein 1 Nucleus other 
KKCC1_HUMAN CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha Cytoplasm kinase 
CAND1_HUMAN CAND1 cullin-associated and neddylation-dissociated 1 Cytoplasm transcription 
regulator 
CBX7_HUMAN CBX7 chromobox homolog 7 Nucleus other 
CCD37_HUMAN CCDC37 coiled-coil domain containing 37 Other other 
CP135_HUMAN CEP135 centrosomal protein 135kDa Cytoplasm other 
CHD9_HUMAN CHD9 chromodomain helicase DNA binding protein 9 Cytoplasm other 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CPN2_HUMAN CPN2 carboxypeptidase N, polypeptide 2 Extracellular 
Space 
peptidase 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CUL9_HUMAN CUL9 cullin 9 Cytoplasm other 
CWC25_HUMAN CWC25 CWC25 spliceosome-associated protein homolog (S. cerevisiae) Other other 
DCD_HUMAN DCD dermcidin Extracellular 
Space 
other 
DCR1B_HUMAN DCLRE1B DNA cross-link repair 1B Nucleus enzyme 
DDX51_HUMAN DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 Other enzyme 
DGC14_HUMAN DGCR14 DiGeorge syndrome critical region gene 14 Nucleus other 
DYH5_HUMAN DNAH5 dynein, axonemal, heavy chain 5 Extracellular 
Space 
enzyme 
DNJC7_HUMAN DNAJC7 DnaJ (Hsp40) homolog, subfamily C, member 7 Cytoplasm other 
EDN1_HUMAN EDN1 endothelin 1 Extracellular 
Space 
cytokine 
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EIF3C_HUMAN EIF3C/EIF3CL eukaryotic translation initiation factor 3, subunit C Cytoplasm translation 
regulator 
ENPP1_HUMAN ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 Plasma 
Membrane 
enzyme 
ESPL1_HUMAN ESPL1 extra spindle pole bodies homolog 1 (S. cerevisiae) Nucleus peptidase 
NIBL2_HUMAN FAM129C family with sequence similarity 129, member C Other other 
FIBA_HUMAN FGA fibrinogen alpha chain Extracellular 
Space 
other 
FIBB_HUMAN FGB fibrinogen beta chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
GLTL5_HUMAN GALNTL5 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 5 
Cytoplasm enzyme 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, soluble Cytoplasm enzyme 
GSAP_HUMAN GSAP gamma-secretase activating protein Cytoplasm peptidase 
GSHB_HUMAN GSS glutathione synthetase Cytoplasm enzyme 
HBG1_HUMAN HBG1 hemoglobin, gamma A Cytoplasm other 
HIP1_HUMAN HIP1 huntingtin interacting protein 1 Cytoplasm other 
BPL1_HUMAN HLCS holocarboxylase synthetase (biotin-(proprionyl-CoA-carboxylase 
(ATP-hydrolysing)) ligase) 
Cytoplasm enzyme 
HNF4A_HUMAN HNF4A hepatocyte nuclear factor 4, alpha Nucleus transcription 
regulator 
HPTR_HUMAN HPR haptoglobin-related protein Extracellular 
Space 
peptidase 
HS3S6_HUMAN HS3ST6 heparan sulfate (glucosamine) 3-O-sulfotransferase 6 Cytoplasm enzyme 
GILT_HUMAN IFI30 interferon, gamma-inducible protein 30 Cytoplasm enzyme 
IBP2_HUMAN IGFBP2 insulin-like growth factor binding protein 2, 36kDa Extracellular 
Space 
other 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
IGJ_HUMAN IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin 
alpha and mu polypeptides 
Extracellular 
Space 
other 
IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
IL25_HUMAN IL25 interleukin 25 Extracellular 
Space 
cytokine 
IL26_HUMAN IL26 interleukin 26 Extracellular 
Space 
cytokine 
INHBB_HUMAN INHBB inhibin, beta B Extracellular 
Space 
growth factor 
JARD2_HUMAN JARID2 jumonji, AT rich interactive domain 2 Nucleus transcription 
regulator 
KIF4B_HUMAN KIF4B kinesin family member 4B Nucleus other 
KLC2_HUMAN KLC2 kinesin light chain 2 Cytoplasm other 
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other 
K1C10_HUMAN KRT10 keratin 10 Cytoplasm other 
K1C14_HUMAN KRT14 keratin 14 Cytoplasm other 
K22E_HUMAN KRT2 keratin 2 Cytoplasm other 
K2C4_HUMAN KRT4 keratin 4 Cytoplasm other 
K1C9_HUMAN KRT9 keratin 9 Cytoplasm other 
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LDB1_HUMAN LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
LY75_HUMAN LY75 lymphocyte antigen 75 Plasma 
Membrane 
transmembrane 
receptor 
MANF_HUMAN MANF mesencephalic astrocyte-derived neurotrophic factor Extracellular 
Space 
other 
MA7D3_HUMAN MAP7D3 MAP7 domain containing 3 Cytoplasm other 
MRE11_HUMAN MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) Nucleus enzyme 
RT18C_HUMAN MRPS18C mitochondrial ribosomal protein S18C Cytoplasm other 
MTOR_HUMAN MTOR mechanistic target of rapamycin (serine/threonine kinase) Nucleus kinase 
MYF6_HUMAN MYF6 myogenic factor 6 (herculin) Nucleus transcription 
regulator 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NCOA2_HUMAN NCOA2 nuclear receptor coactivator 2 Nucleus transcription 
regulator 
NCOA5_HUMAN NCOA5 nuclear receptor coactivator 5 Nucleus other 
NFL_HUMAN NEFL neurofilament, light polypeptide Cytoplasm other 
PSA_HUMAN NPEPPS aminopeptidase puromycin sensitive Cytoplasm peptidase 
NSD1_HUMAN NSD1 nuclear receptor binding SET domain protein 1 Nucleus transcription 
regulator 
NET5_HUMAN NTN5 netrin 5 Other other 
OCEL1_HUMAN OCEL1 occludin/ELL domain containing 1 Other other 
PAR3L_HUMAN PARD3B par-3 family cell polarity regulator beta Plasma 
Membrane 
other 
PCDH8_HUMAN PCDH8 protocadherin 8 Plasma 
Membrane 
other 
SOX_HUMAN PIPOX pipecolic acid oxidase Cytoplasm enzyme 
PK1L1_HUMAN PKD1L1 polycystic kidney disease 1 like 1 Extracellular 
Space 
other 
PLEC_HUMAN PLEC plectin Cytoplasm other 
PNKD_HUMAN PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
PNKP_HUMAN PNKP polynucleotide kinase 3'-phosphatase Nucleus kinase 
PRP31_HUMAN PRPF31 pre-mRNA processing factor 31 Nucleus other 
PRC2A_HUMAN PRRC2A proline-rich coiled-coil 2A Cytoplasm other 
PRS7_HUMAN PSMC2 proteasome (prosome, macropain) 26S subunit, ATPase, 2 Nucleus peptidase 
PTTG3_HUMAN PTTG3P pituitary tumor-transforming 3, pseudogene Other other 
PZP_HUMAN PZP pregnancy-zone protein Extracellular 
Space 
other 
REG1A_HUMAN REG1A regenerating islet-derived 1 alpha Extracellular 
Space 
growth factor 
RFC4_HUMAN RFC4 replication factor C (activator 1) 4, 37kDa Nucleus other 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA binding domain Other other 
RN219_HUMAN RNF219 ring finger protein 219 Other other 
FTM_HUMAN RPGRIP1L RPGRIP1-like Cytoplasm other 
RL29_HUMAN RPL29 ribosomal protein L29 Cytoplasm other 
KS6A4_HUMAN RPS6KA4 ribosomal protein S6 kinase, 90kDa, polypeptide 4 Cytoplasm kinase 
S27A2_HUMAN SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 Cytoplasm transporter 
GTR11_HUMAN SLC2A11 solute carrier family 2 (facilitated glucose transporter), member 11 Plasma 
Membrane 
other 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other 
SIA7B_HUMAN ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
Cytoplasm enzyme 
MENTO_HUMAN STARD3NL STARD3 N-terminal like Cytoplasm other 
STXB1_HUMAN STXBP1 syntaxin binding protein 1 Cytoplasm transporter 
SPT6H_HUMAN SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) Nucleus transcription 
regulator 
Appendix A  
 
 
 
- 117 - 
 
TADA3_HUMAN TADA3 transcriptional adaptor 3 Nucleus transcription 
regulator 
TET1_HUMAN TET1 tet methylcytosine dioxygenase 1 Nucleus other 
TLK2_HUMAN TLK2 tousled-like kinase 2 Cytoplasm kinase 
TRIPB_HUMAN TRIP11 thyroid hormone receptor interactor 11 Cytoplasm transcription 
regulator 
TRPC5_HUMAN TRPC5 transient receptor potential cation channel, subfamily C, member 5 Plasma 
Membrane 
ion channel 
TSC2_HUMAN TSC2 tuberous sclerosis 2 Cytoplasm other 
TTBK2_HUMAN TTBK2 tau tubulin kinase 2 Other kinase 
TITIN_HUMAN TTN titin Other kinase 
UBQLN_HUMAN UBQLNL ubiquilin-like Other other 
UBR2_HUMAN UBR2 ubiquitin protein ligase E3 component n-recognin 2 Nucleus enzyme 
UCKL1_HUMAN UCKL1 uridine-cytidine kinase 1-like 1 Cytoplasm kinase 
UGDH_HUMAN UGDH UDP-glucose 6-dehydrogenase Nucleus enzyme 
UTRO_HUMAN UTRN utrophin Plasma 
Membrane 
transmembrane 
receptor 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
WDR35_HUMAN WDR35 WD repeat domain 35 Cytoplasm other 
WFDC3_HUMAN WFDC3 WAP four-disulfide core domain 3 Extracellular 
Space 
other 
NIPA_HUMAN ZC3HC1 zinc finger, C3HC-type containing 1 Nucleus other 
TUT4_HUMAN ZCCHC11 zinc finger, CCHC domain containing 11 Nucleus enzyme 
ZF64A_HUMAN ZFP64 ZFP64 zinc finger protein Nucleus other 
ZNF14_HUMAN ZNF14 zinc finger protein 14 Nucleus transcription 
regulator 
ZN215_HUMAN ZNF215 zinc finger protein 215 Nucleus transcription 
regulator 
ZN345_HUMAN ZNF345 zinc finger protein 345 Nucleus transcription 
regulator 
ZN624_HUMAN ZNF624 zinc finger protein 624 Nucleus other 
ZN735_HUMAN ZNF735 zinc finger protein 735 Other other 
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11 week (n=10). 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
ACTT1_HUMAN ACTRT1 actin-related protein T1 Cytoplasm other 
ADAL_HUMAN ADAL adenosine deaminase-like Cytoplasm enzyme 
ADA30_HUMAN ADAM30 ADAM metallopeptidase domain 30 Plasma 
Membrane 
peptidase 
ATS16_HUMAN ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif, 16 Extracellular 
Space 
other 
ANGT_HUMAN AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Extracellular 
Space 
growth factor 
AICDA_HUMAN AICDA activation-induced cytidine deaminase Cytoplasm enzyme 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
AMZ1_HUMAN AMZ1 archaelysin family metallopeptidase 1 Other peptidase 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
APOB_HUMAN APOB apolipoprotein B Extracellular 
Space 
transporter 
RHG15_HUMAN ARHGAP15 Rho GTPase activating protein 15 Cytoplasm other 
ASPM_HUMAN ASPM asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila) 
Nucleus other 
ATG2B_HUMAN ATG2B autophagy related 2B Other other 
AT2A3_HUMAN ATP2A3 ATPase, Ca++ transporting, ubiquitous Cytoplasm transporter 
ATR_HUMAN ATR ataxia telangiectasia and Rad3 related Nucleus kinase 
BC11B_HUMAN BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) Nucleus other 
BRCA2_HUMAN BRCA2 breast cancer 2, early onset Nucleus transcription 
regulator 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
CO4A_HUMAN C4A/C4B complement component 4B (Chido blood group) Extracellular 
Space 
other 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
CC171_HUMAN CCDC171 coiled-coil domain containing 171 Other other 
CCD30_HUMAN CCDC30 coiled-coil domain containing 30 Other other 
CCD37_HUMAN CCDC37 coiled-coil domain containing 37 Other other 
CAD26_HUMAN CDH26 cadherin 26 Plasma 
Membrane 
other 
CDK10_HUMAN CDK10 cyclin-dependent kinase 10 Nucleus kinase 
CHD4_HUMAN CHD4 chromodomain helicase DNA binding protein 4 Nucleus enzyme 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CSRN1_HUMAN CSRNP1 cysteine-serine-rich nuclear protein 1 Nucleus transcription 
regulator 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CTRL_HUMAN CTRL chymotrypsin-like Extracellular 
Space 
peptidase 
CX028_HUMAN CXorf28 chromosome X open reading frame 28 Other other 
DCAF6_HUMAN DCAF6 DDB1 and CUL4 associated factor 6 Nucleus transcription 
regulator 
DCD_HUMAN DCD dermcidin Extracellular 
Space 
other 
DDX51_HUMAN DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 Other enzyme 
DEN2D_HUMAN DENND2D DENN/MADD domain containing 2D Cytoplasm other 
DESM_HUMAN DES desmin Cytoplasm other 
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DGAT1_HUMAN DGAT1 diacylglycerol O-acyltransferase 1 Cytoplasm enzyme 
DHX30_HUMAN DHX30 DEAH (Asp-Glu-Ala-His) box helicase 30 Nucleus enzyme 
DYH3_HUMAN DNAH3 dynein, axonemal, heavy chain 3 Extracellular 
Space 
enzyme 
DOP1_HUMAN DOPEY1 dopey family member 1 Cytoplasm other 
EVC_HUMAN EVC Ellis van Creveld syndrome Cytoplasm other 
F150A_HUMAN FAM150A family with sequence similarity 150, member A Other other 
FIBB_HUMAN FGB fibrinogen beta chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FGRL1_HUMAN FGFRL1 fibroblast growth factor receptor-like 1 Plasma 
Membrane 
transmembrane 
receptor 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FIGL2_HUMAN FIGNL2 fidgetin-like 2 Other other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
GCN1L_HUMAN GCN1L1 GCN1 general control of amino-acid synthesis 1-like 1 (yeast) Cytoplasm translation 
regulator 
CXB1_HUMAN GJB1 gap junction protein, beta 1, 32kDa Plasma 
Membrane 
transporter 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, soluble Cytoplasm enzyme 
GRID2_HUMAN GRID2 glutamate receptor, ionotropic, delta 2 Plasma 
Membrane 
ion channel 
HCN2_HUMAN HCN2 hyperpolarization activated cyclic nucleotide-gated potassium 
channel 2 
Plasma 
Membrane 
ion channel 
HES1_HUMAN HES1 hairy and enhancer of split 1, (Drosophila) Nucleus transcription 
regulator 
HS3S6_HUMAN HS3ST6 heparan sulfate (glucosamine) 3-O-sulfotransferase 6 Cytoplasm enzyme 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
IGJ_HUMAN IGJ immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
Extracellular 
Space 
other 
IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
LAC1_HUMAN IGLC1 immunoglobulin lambda constant 1 (Mcg marker) Cytoplasm other 
LAC2_HUMAN IGLC2 immunoglobulin lambda constant 2 (Kern-Oz- marker) Extracellular 
Space 
other 
IL25_HUMAN IL25 interleukin 25 Extracellular 
Space 
cytokine 
IL26_HUMAN IL26 interleukin 26 Extracellular 
Space 
cytokine 
ITK_HUMAN ITK IL2-inducible T-cell kinase Cytoplasm kinase 
KDM2B_HUMAN KDM2B lysine (K)-specific demethylase 2B Nucleus other 
KIRR1_HUMAN KIRREL kin of IRRE like (Drosophila) Plasma 
Membrane 
other 
KLC2_HUMAN KLC2 kinesin light chain 2 Cytoplasm other 
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other 
K1C10_HUMAN KRT10 keratin 10 Cytoplasm other 
K1C14_HUMAN KRT14 keratin 14 Cytoplasm other 
K22E_HUMAN KRT2 keratin 2 Cytoplasm other 
K2C4_HUMAN KRT4 keratin 4 Cytoplasm other 
K1C9_HUMAN KRT9 keratin 9 Cytoplasm other 
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LAMA5_HUMAN LAMA5 laminin, alpha 5 Extracellular 
Space 
other 
LDB1_HUMAN LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
LIPC_HUMAN LIPC lipase, hepatic Extracellular 
Space 
enzyme 
LRP1B_HUMAN LRP1B low density lipoprotein receptor-related protein 1B Plasma 
Membrane 
transmembrane 
receptor 
LTBP2_HUMAN LTBP2 latent transforming growth factor beta binding protein 2 Extracellular 
Space 
other 
MAP4_HUMAN MAP4 microtubule-associated protein 4 Cytoplasm other 
MBIP1_HUMAN MBIP MAP3K12 binding inhibitory protein 1 Nucleus other 
MEX3B_HUMAN MEX3B mex-3 RNA binding family member B Other kinase 
MFNG_HUMAN MFNG MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase Cytoplasm enzyme 
MORC1_HUMAN MORC1 MORC family CW-type zinc finger 1 Nucleus other 
MYO15_HUMAN MYO15A myosin XVA Cytoplasm other 
MYO6_HUMAN MYO6 myosin VI Cytoplasm other 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NCOA5_HUMAN NCOA5 nuclear receptor coactivator 5 Nucleus other 
NFL_HUMAN NEFL neurofilament, light polypeptide Cytoplasm other 
NEK10_HUMAN NEK10 NIMA-related kinase 10 Other kinase 
NRX3A_HUMAN NRXN3 neurexin 3 Other transporter 
NET5_HUMAN NTN5 netrin 5 Other other 
OBSCN_HUMAN OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF Cytoplasm kinase 
PCDBC_HUMAN PCDHB12 protocadherin beta 12 Plasma 
Membrane 
other 
PNKD_HUMAN PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
PPCEL_HUMAN PREPL prolyl endopeptidase-like Other peptidase 
PRG4_HUMAN PRG4 proteoglycan 4 Extracellular 
Space 
other 
PZP_HUMAN PZP pregnancy-zone protein Extracellular 
Space 
other 
RAB10_HUMAN RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
RAB8B_HUMAN RAB8B RAB8B, member RAS oncogene family Cytoplasm enzyme 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA binding domain Other other 
R144B_HUMAN RNF144B ring finger protein 144B Other enzyme 
RRNAD_HUMAN RRNAD1 ribosomal RNA adenine dimethylase domain containing 1 Other other 
RTKN_HUMAN RTKN rhotekin Cytoplasm other 
SACS_HUMAN SACS spastic ataxia of Charlevoix-Saguenay (sacsin) Plasma 
Membrane 
other 
SAMD8_HUMAN SAMD8 sterile alpha motif domain containing 8 Cytoplasm other 
SET1A_HUMAN SETD1A SET domain containing 1A Nucleus ion channel 
SH24A_HUMAN SH2D4A SH2 domain containing 4A Cytoplasm other 
SHAN1_HUMAN SHANK1 SH3 and multiple ankyrin repeat domains 1 Cytoplasm other 
SLN14_HUMAN SLFN14 schlafen family member 14 Other other 
SPAG7_HUMAN SPAG7 sperm associated antigen 7 Nucleus other 
SPTN5_HUMAN SPTBN5 spectrin, beta, non-erythrocytic 5 Plasma 
Membrane 
other 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other 
SRG2C_HUMAN SRGAP2C SLIT-ROBO Rho GTPase activating protein 2C Other other 
SIA7B_HUMAN ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
Cytoplasm enzyme 
SPT6H_HUMAN SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) Nucleus transcription 
regulator 
TBX20_HUMAN TBX20 T-box 20 Nucleus transcription 
regulator 
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TLK2_HUMAN TLK2 tousled-like kinase 2 Cytoplasm kinase 
T132C_HUMAN TMEM132C transmembrane protein 132C Other other 
TNFA_HUMAN TNF tumor necrosis factor Extracellular 
Space 
cytokine 
TRI32_HUMAN TRIM32 tripartite motif containing 32 Nucleus transcription 
regulator 
TROAP_HUMAN TROAP trophinin associated protein Cytoplasm peptidase 
TRPC5_HUMAN TRPC5 transient receptor potential cation channel, subfamily C, 
member 5 
Plasma 
Membrane 
ion channel 
TSG13_HUMAN TSGA13 testis specific, 13 Other other 
TTBK2_HUMAN TTBK2 tau tubulin kinase 2 Other kinase 
TITIN_HUMAN TTN titin Other kinase 
TRXR3_HUMAN TXNRD3 thioredoxin reductase 3 Cytoplasm enzyme 
UBR2_HUMAN UBR2 ubiquitin protein ligase E3 component n-recognin 2 Nucleus enzyme 
MELT_HUMAN VEPH1 ventricular zone expressed PH domain-containing 1 Nucleus other 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
WDR35_HUMAN WDR35 WD repeat domain 35 Cytoplasm other 
ZNF14_HUMAN ZNF14 zinc finger protein 14 Nucleus transcription 
regulator 
ZN561_HUMAN ZNF561 zinc finger protein 561 Nucleus other 
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12 week (n=10). 
ID Symbol Entrez Gene Name Location Type(s) 
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular 
Space 
transporter 
ADAL_HUMAN ADAL adenosine deaminase-like Cytoplasm enzyme 
ANGT_HUMAN AGT angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) 
Extracellular 
Space 
growth factor 
ALBU_HUMAN ALB albumin Extracellular 
Space 
transporter 
AKD1B_HUMAN ANKDD1B ankyrin repeat and death domain containing 1B Other other 
ANR12_HUMAN ANKRD12 ankyrin repeat domain 12 Nucleus other 
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular 
Space 
transporter 
APOB_HUMAN APOB apolipoprotein B Extracellular 
Space 
transporter 
BRCA2_HUMAN BRCA2 breast cancer 2, early onset Nucleus transcription 
regulator 
CO3_HUMAN C3 complement component 3 Extracellular 
Space 
peptidase 
C4BPA_HUMAN C4BPA complement component 4 binding protein, alpha Extracellular 
Space 
other 
CAND1_HUMAN CAND1 cullin-associated and neddylation-dissociated 1 Cytoplasm transcription 
regulator 
CCD80_HUMAN CCDC80 coiled-coil domain containing 80 Nucleus other 
CHSS3_HUMAN CHSY3 chondroitin sulfate synthase 3 Cytoplasm enzyme 
CMBL_HUMAN CMBL carboxymethylenebutenolidase homolog (Pseudomonas) Other enzyme 
COPA1_HUMAN COL25A1 collagen, type XXV, alpha 1 Cytoplasm other 
DIAC_HUMAN CTBS chitobiase, di-N-acetyl- Cytoplasm enzyme 
CP1A2_HUMAN CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 Cytoplasm enzyme 
DCAF6_HUMAN DCAF6 DDB1 and CUL4 associated factor 6 Nucleus transcription 
regulator 
EBP_HUMAN EBP emopamil binding protein (sterol isomerase) Cytoplasm enzyme 
YV021_HUMAN FAM230B family with sequence similarity 230, member B Other other 
FIBA_HUMAN FGA fibrinogen alpha chain Extracellular 
Space 
other 
FIBB_HUMAN FGB fibrinogen beta chain Extracellular 
Space 
other 
FR1OP_HUMAN FGFR1OP FGFR1 oncogene partner Cytoplasm kinase 
FIBG_HUMAN FGG fibrinogen gamma chain Extracellular 
Space 
other 
FIGL2_HUMAN FIGNL2 fidgetin-like 2 Other other 
FINC_HUMAN FN1 fibronectin 1 Extracellular 
Space 
enzyme 
FRMD3_HUMAN FRMD3 FERM domain containing 3 Other other 
GLRA2_HUMAN GLRA2 glycine receptor, alpha 2 Plasma 
Membrane 
ion channel 
GOGA3_HUMAN GOLGA3 golgin A3 Cytoplasm transporter 
AATC_HUMAN GOT1 glutamic-oxaloacetic transaminase 1, soluble Cytoplasm enzyme 
GSAS1_HUMAN GSN-AS1 GSN antisense RNA 1 Other other 
HERC1_HUMAN HERC1 HECT and RLD domain containing E3 ubiquitin protein 
ligase family member 1 
Cytoplasm other 
I23O2_HUMAN IDO2 indoleamine 2,3-dioxygenase 2 Cytoplasm enzyme 
IGHA1_HUMAN IGHA1 immunoglobulin heavy constant alpha 1 Extracellular 
Space 
other 
IGHG1_HUMAN IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) Extracellular 
Space 
other 
IGHM_HUMAN IGHM immunoglobulin heavy constant mu Plasma 
Membrane 
transmembrane 
receptor 
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IGKC_HUMAN IGKC immunoglobulin kappa constant Extracellular 
Space 
other 
KV401_HUMAN IGKV4-1 immunoglobulin kappa variable 4-1 Extracellular 
Space 
other 
LAC1_HUMAN IGLC1 immunoglobulin lambda constant 1 (Mcg marker) Cytoplasm other 
IRPL2_HUMAN IL1RAPL2 interleukin 1 receptor accessory protein-like 2 Plasma 
Membrane 
transmembrane 
receptor 
KI13A_HUMAN KIF13A kinesin family member 13A Cytoplasm transporter 
KLRF1_HUMAN KLRF1 killer cell lectin-like receptor subfamily F, member 1 Plasma 
Membrane 
transmembrane 
receptor 
LDB1_HUMAN LDB1 LIM domain binding 1 Nucleus transcription 
regulator 
KLP6_HUMAN LOC100130097 kinesin-like protein family member 6-like Cytoplasm other 
MACD1_HUMAN MACROD1 MACRO domain containing 1 Cytoplasm enzyme 
MLP3A_HUMAN MAP1LC3A microtubule-associated protein 1 light chain 3 alpha Cytoplasm other 
MYO3A_HUMAN MYO3A myosin IIIA Cytoplasm kinase 
ULA1_HUMAN NAE1 NEDD8 activating enzyme E1 subunit 1 Cytoplasm enzyme 
NRX3A_HUMAN NRXN3 neurexin 3 Other transporter 
PARP4_HUMAN PARP4 poly (ADP-ribose) polymerase family, member 4 Other enzyme 
PCLO_HUMAN PCLO piccolo presynaptic cytomatrix protein Cytoplasm transporter 
PEG10_HUMAN PEG10 paternally expressed 10 Nucleus other 
PLXA4_HUMAN PLXNA4 plexin A4 Plasma 
Membrane 
transmembrane 
receptor 
PNKD_HUMAN PNKD paroxysmal nonkinesigenic dyskinesia Nucleus other 
PRG4_HUMAN PRG4 proteoglycan 4 Extracellular 
Space 
other 
REG1A_HUMAN REG1A regenerating islet-derived 1 alpha Extracellular 
Space 
growth factor 
RFX8_HUMAN RFX8 RFX family member 8, lacking RFX DNA binding domain Other other 
RNF17_HUMAN RNF17 ring finger protein 17 Cytoplasm other 
FTM_HUMAN RPGRIP1L RPGRIP1-like Cytoplasm other 
KS6A4_HUMAN RPS6KA4 ribosomal protein S6 kinase, 90kDa, polypeptide 4 Cytoplasm kinase 
SHAN1_HUMAN SHANK1 SH3 and multiple ankyrin repeat domains 1 Cytoplasm other 
SNTAN_HUMAN SNTN sentan, cilia apical structure protein Other other 
SOLH1_HUMAN SOHLH1 spermatogenesis and oogenesis specific basic helix-loop-
helix 1 
Cytoplasm transcription 
regulator 
CYTSB_HUMAN SPECC1 sperm antigen with calponin homology and coiled-coil 
domains 1 
Nucleus other 
SRGP2_HUMAN SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other 
SYNJ1_HUMAN SYNJ1 synaptojanin 1 Cytoplasm phosphatase 
TBX20_HUMAN TBX20 T-box 20 Nucleus transcription 
regulator 
THMS1_HUMAN THEMIS thymocyte selection associated Cytoplasm other 
T151A_HUMAN TMEM151A transmembrane protein 151A Other other 
TTC12_HUMAN TTC12 tetratricopeptide repeat domain 12 Other other 
GCP6_HUMAN TUBGCP6 tubulin, gamma complex associated protein 6 Cytoplasm other 
UBQLN_HUMAN UBQLNL ubiquilin-like Other other 
WDR1_HUMAN WDR1 WD repeat domain 1 Extracellular 
Space 
other 
WDR35_HUMAN WDR35 WD repeat domain 35 Cytoplasm other 
ZN532_HUMAN ZNF532 zinc finger protein 532 Other other 
ZN624_HUMAN ZNF624 zinc finger protein 624 Nucleus other 
ZNF74_HUMAN ZNF74 zinc finger protein 74 Nucleus other 
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Appendix C: List of Abbreviations 
APC     Antigen Presenting Cell 
ACN    Acetonitryl 
BMI     Body Mass Index 
BSA  Bovine Serum Albumin 
CD  Cluster of Differentiation 
CERF  Collaborative Electronic Research Framework 
cP  CentiPoise 
DTT  Dithiothreitol 
ELISA  Enzyme Linked Immunosorbent Assay 
EDTA  Ethylenediaminetetraacetic acid 
FGF  Fibroblast Growth Factor 
GDM  Gestational Diabetes Mellitus 
HAPO  Hyperglycaemia and Adverse Pregnancy Outcome 
HCG  Human Chorionic Gonadotrophin 
HPL  Human Placental Lactogen 
Hsp  Heat Shock Protein 
Hsc  Heat Shock Cognate 
HbA1c  Glycated haemoglobin 
HRP  Horse Radish Peroxidase 
IPA  Ingenuity Pathway Analysis 
IGF  Insulin like Growth Factor 
IUGR  Intrauterine Growth Restriction 
IAA  Iodoacetamide 
IR  Immunoreactive 
IL  Interleukin 
IFN  Interferon 
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LC-MS  Liquid Chromatography - Mass Spectrometry 
MVB   Multivesicular bodies 
miRNA  micro RNA 
mRNA   messenger RNA 
MHC   Major Histocompatibility Complex 
MV   Microvesicle 
MD   Doctor of Medicine 
NTA   Nanoparticle Tracking Analysis 
NEP   Number of Exosome Particle 
OGTT   Oral Glucose Tolerance Test 
PE   Preeclampsia 
PLAP   Placental Alkaline Phosphatase 
PANTHER  Protein Analysis Through Evolutionary Relationships 
PBS   Phosphate Buffered Saline 
PAPP-A  Pregnancy Associated Plasma Protein –A 
ROS   Reactive Oxygen Species 
RIPA   Radioimmunoprecipitation assay 
RT   Room Temperature 
SD   Standard Deviation 
SEM   Standard Error of Mean 
TEM   Transmission Electron Microscopy 
TNF   Tumour Necrosis Factor 
TFA   Trifluoroacetic acid 
TOF   Time of Flight 
TFP   Tissue Factor Protein 
UQCCR  University of Queensland Centre for Clinical Research 
VEGF   Vascular Endothelial Growth Factor 
